Human normal immunoglobulin/Alternative Treatment Page 1of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALTITLE PAGE – REGISTRY INFORMATION
PROTOCOL TITLE Pregnancy Registry to collect Long -Term  Safety Data from 
Wom entreated with HyQvia 
PROTOCOL ID # 161301
AMENDMENT Amendment 3: 22OCT 2015
Replaces  Amendment 2: 0 9APR 2015
Amendment 1: 03 FEB 2015
Original: 27JUN 2013
EU PAS /
CLINICAL TRIALS.GOV/ 
OTHER REGISTER #ENC ePP/SDPP/5798
Study ID: [REMOVED]
IND NUMBER: 013840
MEDICINAL PRODUCT
Active Ingredient(s) Human normal immunoglobulin /Alternative treatment
Medicinal Product HyQvia/ HYQVIA [Immune Globulin Infusion 10% (Human) 
with rHuPH20 ]orHuman normal immunoglobulin for 
intravenous or subcutaneous infusion /Alternative treatment
PRODUCT REF. # EU/1/13/840/001 -005
USA: BL 125402
PROCEDURE # EMEA/H/C/002491
USA:  Not Applicable
MARKETING AUTHORISATION 
HOLDER (MAH)EU: Baxalta Innovations GmbH, Industriestrasse 67, 
A-1221 Vienna, Austria
USA : Baxalta US Inc. , One Baxter Way,
Westlake Village, CA 91362
JOINT PASS No
RESEARCH QUESTION & OBJECTIVES
Research Question
The purpose of th isregistry is to acquire safety data (including assessment of anti-rHuPH20 antibodies), 
regarding the course and outcome of pregnancy in women ever treated with HyQvia. Development of the 
fetus/infant at birth and for the first 2 years will also be followed.
Prim ary Objective
To collect and assess clinical safety data regarding the possible effects of HyQvia on the course and 
outcome of pregnancy, and on the growth and development of the fetus/infant .
Secondary Objective(s)
To collect any laboratory safety data and additional safety assessments obtained during the clinical 
management of the pregnancy or in the evaluation of the fetus in utero and the infant post partum .
COUNTRY( -IES) OF STUDY European Economic Area, North America , and other countries, 
where the product is licensed, as needed
AUTHOR
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 2of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALMAR KETING AUTHORIZATION HOLDER(S)
MAH EU: Baxalta Innovations GmbH, Industriestrasse 67,
A-1221 Vienna, Austria
USA : Baxalta US Inc. , One Baxter Way,
Westlake Village, CA 91362
MAH CONTACT 
PERSON  
Baxalta US Inc.
SERIOUS ADVERSE EVEN TREPORTING
The investigator will comply  with applicable laws/requirements for reporting serious 
adverse events (SAEs) to the ethics committee( s)(ECs) . 
ALL SAEs ARE TO BE REPORTED ON THE 
ADVERSE EVENT ELECTRONIC CASE REPORT FORM (ECRF) WITHIN 
24 HOURS AFTER BECOMING AWARE OF THE EVENT. IF THE ECRF IS 
NOT AVAILABLE ,OR IF THE SITE IS COORDINATED BY THE MAH’S 
REPRESENTATIVE, THE SAE MUST BE REPORTED ON THE SERIOUS 
ADVERSE EVENT REPORT (SAER) FORM AND TRANSMITTED TO THE 
MAH /MAH REPRESENTATIVE TO M EET THE 24 HOUR TIMELINE 
REQUIREMENT.
See SAER form for contact information.
Further details are also available in the study team roster.
For information on the assessment and definitions of these events refer to: assessment of 
adverse events (AEs) in Section 11.1, and definitions of AE in Section 11.2, SAE in 
Section 11.2.2.
NON
-SERIOUS ADVERSE EVEN T REPORTING
Any non- serious adverse events (including the associated concomitant medications) , all 
therapies/procedures to treat the AEs, and the outcome of the AEs a re to be reported to 
the MAH /MAH’s representative(s) on the appropriate case report forms (CRFs) within 
5 business day s. If the site is coordinated by the MAH’s representative, data will be 
entered on the Non-Serious Adverse Event Report Form and transmitted to the 
MAH/MAH ’srepresentative (see Non-Serious Adverse Event Report Form for contact 
information) .
If the eCRF is not available for more than 14 business day s, then the AE must be reported 
on the Non
-Serious Adverse Event Report Form and transmitted to the MAH /MAH ’
representative (see Non- Serious Adverse Event Report Form for contact information).
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 3of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL1.TABLE OF CONTENTS
TITLE PAGE – REGISTRY INFORMATION ............................................................ 1
MARKETING AUTHORIZAT ION 
HOLDER(S) ........................................................ 2
SERIOUS ADVERSE EVEN T REPORTING ............................................................... 2
NON
-SERIOUS ADVERSE EVEN T REPORTING ..................................................... 2
1.TABLE OF CONTENTS ............................................................................................. 3
2. LIST OF ABBREVIAT IONS ...................................................................................... 7
3.RESPONSIBLE PARTIES .......................................................................................... 9
3.1 MAH’s Authorized Representative (Signatory) ................................................... 9
3.2 Investigator(s) .......................................................................................................... 9
3.3 Other Individuals Involved in the Study .............................................................. 9
4. ABSTRACT ................................................................................................................. 10
5. AMENDMENTS AND UP
DATES ............................................................................ 12
6. MILESTONES ............................................................................................................ 12
7. RATIONALE AND BAC KGROUND ...................................................................... 13
7.1 Medicinal Product Safety Profile
........................................................................ 13
7.2 Critical Review of Available Data
....................................................................... 18
7.2.1 Clinical Study 160602 .................................................................................... 19
7.2.2 Clinical Study 160603 .................................................................................... 20
7.2.3 Clinical Study 160902 .................................................................................... 23
7.2.4 Clinical Study 161101 .................................................................................... 27
7.2.5
HyQvia PASS 161302 .................................................................................... 29
7.2.6
HYQ VIA Study 161406 ................................................................................. 30
8. RESEARCH QUESTION
AND OBJECTIVES ................................ ...................... 30
8.1 Research Question ................................................................................................ 31
8.2 Primary Objective ................................................................................................. 31
8.3 Secondary Objectives
........................................................................................... 31
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 4of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL8.3.1 Safety ............................................................................................................... 31
9. RESEARCH METHODS ................................ ................................ ........................... 32
9.1 Study Design .......................................................................................................... 32
9.1.1 Primary Endpoint .......................................................................................... 33
9.1.2 Secondary Endpoints ..................................................................................... 33
9.1.2.1 Safety ........................................................................................................ 33
9.2 Setting
.................................................................................................................... 34
9.2.1 Medicinal Product(s) ..................................................................................... 34
9.2.2 Duration of Study Period(s) and Subject Participation .............................
35
9.2.3 Subject Selection Criteria ............................................................................. 35
9.2.3.1 Inclusion Criteria
.................................................................................... 35
9.2.3.2 Exclusion Criteria
................................................................................... 35
9.2.4 Informed Consent and Enrollment .............................................................. 35
9.2.5 Subject Identification Code .......................................................................... 35
9.2.6 Screening and Study Visits ........................................................................... 36
9.2.7 Subject Withdrawal and Discontinuation ................................................... 40
9.2.8 Study Stopping Rules .................................................................................... 40
9.3 Variables ................................................................................................................ 40
9.3.1 Safety V ariables
............................................................................................. 40
9.3.1.1 Variables for Pregnancy, Pregnancy Outcome, and Infant Follow -up
.................................................................................................................. 40
9.3.2 Medical History, Interval Medical History, Medications, and Non -Drug 
Therapies ........................................................................................................ 42
9.3.3 Physical Examinations ................................................................................... 43
9.3.4 Clinical Laboratory Parameters .................................................................. 43
9.3.4.1 rHuPH20 antibodies ............................................................................... 44
9.3.4.2 Hematology and Clinical Chemistry ..................................................... 44
9.3.4.3 Urinalysis ................................................................................................. 44
9.3.4.4 Antenatal Diagnostics ............................................................................. 44
9.3.4.5 Biobanking ................................ ................................ .............................. 45
9.3.5 Vital Signs ....................................................................................................... 45
9.3.6 Subject Completion/Discontinuation ........................................................... 45
9.4 Data Sources .......................................................................................................... 46
9.4.1 Source Data .................................................................................................... 46
9.5 Study Size ............................................................................................................... 46
9.6 Data Management ................................................................................................. 46
9.6.1 Data Collection Methods
............................................................................... 46
9.6.2 Software .......................................................................................................... 47
9.7 Data Analysis ......................................................................................................... 47
9.7.1
Datasets and Analysis Cohorts ..................................................................... 47
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 5of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL9.7.2 Handling of Missing, Unused, and Spurious Data ...................................... 47
9.7.3 Methods of Analysis
....................................................................................... 48
9.7.3.1 Primary Endpoint
................................................................................... 48
9.7.3.2 Secondary Endpoints .............................................................................. 48
9.7.4 Planned Interim Analysis of the Study ........................................................ 48
9.8 Quality Control ..................................................................................................... 49
9.8.1 Investigator’s Responsibility ......................................................................... 49
9.8.2 Direct Access to Source Data/Documents ................................ .................... 49
9.8.3 Training .......................................................................................................... 49
9.8.4 Monitori ng...................................................................................................... 50
9.8.5 Auditing .......................................................................................................... 50
9.8.6 Non -Compliance with the Protocol .............................................................. 50
9.9 Limitations of the Research Methods ................................................................. 50
9.10 Other Aspects ...................................................................................................... 50
10. PR
OTECTION OF HUMAN SU BJECTS ............................................................. 51
10.1 Compliance Statement
........................................................................................ 51
10.2 Subject Privacy ................................................................................................... 51
10.3 Institutional Review Board/Ethics Committee(s) and Regulatory Authorities
................................................................................................................................ 51
10.4 Informed Consent ............................................................................................... 51
11. MANAGEMENT AND R EPORTING OF ADVERSE EVENTS/ADVERSE 
REACTIONS
............................................................................................................... 53
11.1 Assessment of Adverse Events ........................................................................... 53
11.2 Definitions ............................................................................................................ 54
11.2.1 Adverse Events ............................................................................................. 54
11.2.2 Serious Adverse Event ................................................................................. 54
11.2.3 Non -Serious Adverse Event ........................................................................ 55
11.2.4 Severity ......................................................................................................... 55
11.2.5 Causality ....................................................................................................... 56
11.2.6 Safety Reporting
.......................................................................................... 57
11.2.7 Preexisting Diseases ..................................................................................... 58
11.2.8 Unexpected Adverse Events ........................................................................ 58
11.3 Non -Medical Complaints ................................................................................... 59
12. PLANS FOR DISSEM INATING AND COMMUNIC ATING STUDY RESULTS
...................................................................................................................................... 59
13.REFERENCES ................................ ................................ ................................ .......... 60
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 6of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL14. ANNEXES ................................................................................................................. 65
14.1 List of Stand -Alone Documents ......................................................................... 65
14.2 ENCePP Checklist for Study Protocols ............................................................ 65
14.3 Additional Information ...................................................................................... 65
14.4 Summary of Changes .......................................................................................... 66
INVESTIGATOR ACKNOWL EDGEMENT .............................................................. 67
Tables
Table 1.Pharmacokinetic Parameters of Hy Qvia Compared to Intravenous 
Administration of I G 10% ................................................................................................ 22
Table 2.Schedule of Study  Procedures and Assessments for the Expectant Mother ......
38
Table 3.Schedule of Study  Procedures and Assessments for the Infant ......................... 39
Table 4. Clinical Laboratory  Assessments for the Expectant Mother, if available ......... 39
Table 5.Clinical Laboratory  Assessments for the Infant, if available............................. 40
Figures
Figure 1.Study  Design for Baxalta Clinical Study 161301 ............................................. 37
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 7of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL2. LIST OF ABBREVIATIONS
Abbreviation Definition
AE adverse event
AFP alpha-fetoprotein
CHMP Committee for Medicinal Products for Human Use
B19V parvovirus B19
CLL chronic l ymphocy tic leukemia
CVS chorionic villi biopsy
CRF case report form
CRO contract research organization
EC ethics committee
eCRF electronic case report form
EDC electronic data capture
EMA European Medicines Agency
ENCePP European Network of Centres for Pharmacoepidemiology  and 
Pharmacovigilance
FDA Food and Drug Administration
GCP Good Clinical Practice
HAV hepatitis A virus
HBV hepatitis B virus
HCV hepatitis C virus
HEV hepatitis E virus
HIV human immunodeficiency  virus
HyQvia /HYQVIA Immune Globulin Infusion 10% (Human) with rHuPH20
ICF informed consent form
IG 10% Immune Globulin 10% 
IgG immunoglobulin G
IGI Immune Globulin I nfusion (Human)
IGIV immune globulin intravenous (human)
IgM immunoglobulin M
IRB institutional review board
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 8of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALAbbreviation Definition
IV intravenous(l y)
MAH marketing authorization holder
MM multiple my eloma
PASS Post-Authorization Safety  Surveillance
PIDD primary  immunodeficiency  disease(s)
PSUR periodic safety  update report
rHuPH20 recombinant human h yaluronidase
SAE serious adverse event
SAER serious adverse event report
SC subcutaneous(l y)
SIC subject identification code
SOC System Organ Class
SPC summary  of product characteristics
VASBIs validated acute serious bacterial infections
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 9of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL3.RESPONSIBLE PARTIES
3.1MAH’s Authorized Representative (Signatory) 
 
Baxalta US Inc.
3.2Investigator(s)
The name and contact information of allinvestigators will be maintained by the 
MAH /MAH’s representative(s) in a separate file 
.
3.3Other Individuals Involved in the Study
The name and contact information of other individua ls involved with the study  
(eg,MAH’s /MAH’s representative(s) medical expert and study  monitor, MAH’s 
representative(s), laboratories, steering committees, and oversight committees (including 
ethics committees [ECs]), as applicable) will be maintained b y the MAH/MAH’s 
representative(s) and provided to the investigator (see Annex 14.1) .
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 10of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL4.ABSTRACT
Title :Pregnancy Registry to collect Long -Term  Safety Data from Women treated with HyQvia 
Protocol Amendment 3: 22OCT 2015
Replaces Protocol Amen dment 2: 09 APR 2015
Protocol Amendment 1: 03 FEB 2015
Original Protocol: 27 JUN 2013
Main Author: , Baxalta.
Rationale and background :This pregnancy registry with regular assessment of anti-rHuPH20 antibodies 
wasa commitment tothe Committee for Medicinal Products for Human Use (CHMP) and the Food and 
Drug Administration ( FDA )in the course of the Hy Qvia Marketing Authorization Procedure. Further data 
shall be collected to evaluate safety of women who bec ome pregnant during or after treatment with HyQvia
as well as the physical and neurological development of the infant during the first 2 years of life .
Research question and objectives :The purpose of th isregistry is to acquire safety data (including 
assessment of anti-rHuPH20 antibodies) regarding the course and outcome of pregnancy in women ever 
treated w ith HyQvia. Development of the f etus/infant at birth and for the first 2 years will also be follow ed.
The primary objective is to collect ,and assess ,clinical safety data regarding the possible effects of HyQ via 
on the course and outcome of pregnancy, and on growth and development of the fetus/ infant .The 
secondary objectives are to coll ect any laboratory safety data and additional safety assessments obtained 
during the clinical management of the pregnancy or in the evaluation of thefetus inutero and the infant 
post partum.
Study design :This study is a non-interventional, prospective, uncontrolled, two-arm, open -label, 
multicenter , post-authorization pregnancy registry . Subjects who prior to the study receive d HyQvia and at 
enrollment receive a licensed human normal immunoglobulin other than HyQvia or an alternative treatment
during the study will be assigned to Study Arm 1 (Alternative Product Arm) ; subjects in countries, where 
HyQvia treatment during pregnancy is not indicated, should be enrolled in this arm .
Subject s who continue 
treatment with H yQvia during pregnancy will be follow ed in Study Arm 2 (HyQvia Arm) .
Population :In this registry wom enever treated with HyQvia will be enrolled . In the EU the therapeutic 
indications for HyQvia are Primary Immunodeficiency Diseases ( PIDD )
,Chronic Lymphocytic Leukemia
(CLL ), and Myelom a; in the USA HyQvia is licensed for the treatment of PIDD. Licensure in other 
countries will follow . Although the target population consists mainly of women treated for the approved 
indications in the respect ive country, any woman who becomes pregnant after being exposed to HyQvia 
will be encouraged to participate in the registry.
Product:
In Europe the product is licensed under the trade name HyQvia, in the USA the trade name is HYQVIA 
[Immune Globulin Infusi on 10% (Human) with Recombinant Human Hyaluronidase]. 
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 11of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALSubjects who stop HyQvia treatment will be fol lowed inStudy Arm 1 (Alternat ive Product Arm ).The 
treating physician of the pregnant woman will prescribe a licensed human normal immunoglobulin other 
than HyQvia or an alternative treatment. 
Subjects who continue treatment with HyQvia while pregnan twill be assigned to Study Arm 2 (HyQvia
arm).
Product information such as dosage and dosage regimen for th emedicinal product saredescribed in the 
respective package insert /Summary of Product Characteristics ( SPC). 
Duration of Study Period and Subject Participation:
The overall duration of the study is approximately 6 years from study initiation (Registry ready to enroll) to 
study completion (ie, e nd data collection). The enrollment period is expected to be 3 years.
The  participation period for the pregnant woman is from enrollment to delivery/ end of pregnancy . The 
participation period for the infant is from enrollment until the age of 2 years to assess the development, 
unless prematurely discontinued.
Variables :Visits to the investigator (for example immunologist) and all other medical care w ill be 
performed as is standard for the site and for the subject’s healthcare. How ever, the pregnant subje ct will be 
invited to return approximately every 3 months to the site for blood samples to be taken to assess anti-
rHuPH20 antibodies, as requested by the CHMP and the FDA .For subjects w ith an anti -rHuPH20 antibody 
titer ≥10,000, antibody characterizatio n will be performed. Variables assessed include anti-rHuPH20 
antibodies (rHuPH20 -binding and neutralizing antibodies) of the mother, f etal developm ent characteristics 
such as fetal organ screening (by u ltrasound ), data on the pregnancy and delivery/end of pregnancy , 
neonatal information, infant’s grow th and development , if available .
Data sources :Source data comprise eg ,hospital records, medical records, clinical and office charts , 
laboratory notes, outcomes reported by subject, recorded data from automa ted instruments, subject files, 
records kept at the laboratories and at medico -technical departments involved in the study . 
Study size :There is no minimum sample size pre- specified for this registry. 
Data analysis :Statistical analyses and d ata displays will be descriptive .Data from all enrolled subjects 
will be included in the analyses. Data will be analysed separately according to Study Arm1 or 2 ,and in a 
combined dataset. If the treatment of the pregnant subject is changed in the course of the study, the subject 
will continue to be follow ed in the study arm assigned initially ,for the remaining observation period .
Milestones :
Registry ready to enroll: EU:201 4, USA: 2015
End of data collection: EU: 2021 , USA: 2021
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 12of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL5.AMENDMENTS AND UPDAT ES
Amd.
No.Date Section of 
ProtocolAmendment Reason
1 03 FEB 2015 Throughout 
the protocolRefer to Section 14.4 for 
the Summary of ChangesThe original protocol for the 
European Registry was expanded to 
a global Registry to fulfill the 
commitment to the FDA .The FDA 
required to establish and maintain a 
pregnancy registry for women ever 
treated w ith HyQvia .
2 09 APR 2015 Throughout 
the protocolRefer to Section 14.4 for 
the Summary of ChangesAdministrative
3 22OCT 2015 Throughout 
the protocolRefer to Section 14.4 for 
the Summary of ChangesLanguage change regarding 
pregnancy , breast -feeding and 
fertility in the EU SPC ; update of 
safety reporting; addition of 
characterization of anti-rHuPH20
antibodies
6.MILESTONES
Milestone Date/ Planned Date
EU: Final protocol submission 05SEP 2013 (endorsed by PRAC)
19SEP 2013 (adopted by CHMP)
USA: Final protocol submission 27 FEB 2015
Registration in EU PAS Register 28FEB 2014
Registration in US Database 21 SEP 2015
Registry ready to enrol EU: 201 4
USA: 2015
End of data collection EU: 2021
USA: 2021
Study Progress Report EU: With every PSUR , but at least annually
USA: Annual Status Report on Postmarketing studies
Final Report of Study Results 2021
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 13of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL7.RATIONALE AND BACKGROUND
7.1 Medicinal Product Safety Profile
In this registry , women ever treated with HyQvia who bec ome pregnant will be enrolled . 
In Europe the product is licensed under the trade name Hy Qvia, in the USA the trade 
name is HYQVIA [Immune Globulin I nfusion 10% (Human) with Recombinant Human 
Hyaluronidase]. 
HyQvia is a product dual vial unit consisting of one vial of human normal 
immunoglobulin (I mmune Globulin 10% or IG 10%) and one vial of recombinant human 
hyaluronidase (rHuPH20 )i. 
The IG 10% component provides the therapeutic effect of this medicinal product. The 
recombinant human h yaluronidase facilitates the dispersion and absorption of IG 10%.
Human normal immunoglobulin contains mainly  immunoglobulin G (IgG) with a broad 
spectrum of opsonising and neutralizing antibodies against infectious agents.
Human normal immunoglobulin contains the IgG antibodies present in the normal 
population. I t is usuall y prepared from pooled human plasma from not fewer than 
1,000 donations. I t has a distribution of IgG subclasses closel y proportional to that in 
native human plasma. Adequate doses of human normal immunoglobulin may  restore 
abnormall y low IgG levels to the normal range.
rHuPH20 is a soluble recombinant form of human hy aluronidase th
at modifies the 
permeabilit y of connective tissue through the h ydrolysis of hy aluronan. Hyaluronan is a 
polysaccharide found in the intercellular matrix of connective tissue and of certain 
specialized tissues. I t is degraded by  naturall y occurring h yaluronidase and has a very  fast 
natural turnover in subcutaneous tissue. As a permeation enhancer, rHuPH20 temporaril y 
accelerates the break -down of hy aluronan, resulting in a temporary increase in the 
permeabilit y of the interstitial matrix that facilitates mor e rapid dispersion and absorption 
and improved bioavailability  of the IG 10%.
                                                
irHuPH20 is a highly purified, neutral pH -active human hyaluronidase that is generated by recombinant 
DNA technology. rHuPH20 is the active pharmaceutical ingredient in the marketed product  Hylenex® 
recombinant (hyaluronidase human injection), which is a registered trademark of Halozyme 
Therapeutics, Inc.
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 14of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALHyQvia therapeutic indications include:
EU: Hy Qvia is approved in the EU for
Replacement therap y in adults ( ≥18 years) in primary  immunodeficiency  
syndromes such as:
congenital agammaglobulinaemia and h ypogammaglobulinaemia
common variable immunodeficiency
severe combined immunodeficiency
IgG subclass deficiencies with recurrent infections
Replacement therap y in adults ( ≥18 years) in m yeloma or chronic l ymphocy tic 
leukemia ( CLL ) with severe secondary  hypogammaglobulinaemia and recurrent 
infections
USA: HYQVIA is an immune globulin with recombinant human hyaluronidase indicated 
for the treatment of primary  immunodeficiency  (PI) in adults. This includes, but is not 
limited to, commo n variable immunodeficiency (CVID), X- linked agammaglobulinemia, 
congenital agammaglobulinemia, Wiskott -Aldrich sy ndrome, and severe combined 
immunodeficiencies.
In other countries Hy Qvia is currently  under assessment for marketing authorization.
The backg round of immunoglobulin treatment without/with rHuPH20 in these indications 
is described below.
During th isstudy  the medicinal product is either Hy Qvia (Study  Arm 2) or an alternative 
product (Study  Arm 1), see Section 9.1Study  Design. The safet y data for the selected 
product is described in the package insert/Summary  of Product Characteristics (SPC) of 
the respective product.
A.) Immunoglobulin Treatment
Defe ctive antibod y formation ,with or without decreased levels of serum 
immunoglobulins, is the most common abnormality  in the majorit y of PIDD. I tleads to 
increased susceptibility to viral and bacterial infections, especially  of the sinopulmonary  
and gastroi ntestinal tracts. Decreased immunoglobulin levels are found not only  in the 
group made up predominantly  of antibody  defects (e.g., X-linked agammaglobulinemia, 
selective IgG subclass deficiency , common variable immunodeficiency , or X -linked 
hyperimmunoglobulin M sy ndrome ),but also in the group of combined 
immunodeficiencies (e.g., severe combined immunodeficiency ,Wiskott- Aldrich 
Syndrome )that have defects in both T -and B -cells.1
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 15of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALImmunoglobulin treatment to prevent infections is also performed in Secondary  
Immunodeficiencies, such as chronic l ymphocy tic leukemia ( CLL ) ormultiple my eloma 
(MM) . CLL is the most frequent form of leukemia in Western countries. It is 
characterized b y the clonal proliferation and accumulation of neoplastic B ly mphocy tes 
in the blood, bone marrow, ly mph nodes, and spleen.2MM is a plasma -cell neoplasm that 
is characterized b y skeletal destruction, renal failure, anemia, h ypercalcemia but also 
recurrent infections .3
Individuals with PIDDrequire lifelong replacement therapy  with immunoglobulin 
products to prevent or reduce the severit y of infections. Initially , immunoglobulin
replacement therap y was given b y the intramuscular route , however, since the early  
1980s in the US, the overwhelming majorit y of patients have been treated by the 
intravenous ( IV)route . In the past several years subcutaneous (SC) administration has 
gained popularit y. Currently, the majorit y of immunoglobulin products in the US are 
licensed for IV administration; though , in December 2005, the first SC preparation was 
licensed b y ZLB -Behring.4,5SC administration of immunoglobulin preparations for PIDD 
patients has been accepted in many  countr ies worldwide and is the predominant mode in 
the Scandinavian countries, particularly  in Sweden. The first attempts ,in the late 1970s,
used intramuscular preparations administered atslow infusion rates, but in later years 
rapid infusion rates have been u sed more successfully .6;7;8;9;10
All of the gammaglobulin preparations licensed for SC use are formulated at 10 -20%. 
Commonly  they  are formulated at 16 % and are similar to Cohn Fraction II , therefore ,
they cannot be infused intravenousl y. The higher concentration ,relative to IV 
preparations that are formulated at 5 to 12%
,allows for a smaller infusion volume. This 
method of immunoglobulin replacement t herap y is considered to be effective, safe and 
also highl y appreciated by patients ,as it has a low risk of sy stemic adverse reactions. 
When given weekl y or every  other week, SC IgG leads to higher trough serum IgG 
concentrations than monthly  IV infusions (at the same monthly  dose) .11,12After adequate 
training b y healthcare professionals, SC infusions of immunoglobulin can easily be 
performed b y manypatients at home, thus increasing patient comfort and independence 
and reducing cost.13
Immunoglobulin administered intravenously  is immediately  available in the blood, 
andslowly  equilibrates to the extra -vascular compartment over 3 to 5 day s.14
Subcutaneously administered immunoglobulin is slowly  absorbed from the SC space 
intothe blood and at the same time equilibrates with the extra- vascular compartment. 
Consequently , there is no high spike in the IgG concentration as is seen following IV 
infusion. A study  in 1972 by  Smith, et al., used pharmacokinetic modeling and 
determined that the bioavailability  of SC and IM was 100% when compared to IV .15
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 16of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALMore recent studies mandated b y the FDA showed that the bioavailability  (measure das 
the AUC of immune globulin concentr ation over time) of SC immunoglobulin is lower 
than that of IV immunoglobulin .5,16  Accordingl y, it is recommended that the dose of SC 
immunoglobulin be adjusted to 137
-153% of the IV dose to provide a comparable IgG 
exposure .5,17  Despite the technical difficulties of comparing AUC for 2 different routes 
and frequencies of administration, studies of intradermall y administered immuno
globulin 
in ratsiisuggest that there is decreased bioavailability  through the SC route. 
This may  be due to the mode of absorption of large protein molecules, which cannot 
readil y diffuse through the capillary walls and must be absorbed via the lymphatics .18
The primary  practical disadvantage of SC administration of immunoglobulin is that only  
small volumes can be infused at each site, necessitating the use of multiple sites on a 
weekl y or biweekl y (every -other -week) basis. Generall y, using a 16% solution, 
approximately  20mL can be infused per site; an adult patient receiving 400 mg/kg body  
weight thus would require at least 3 sites per week or 12 sites per month. Even though 
weekl y or biweekl y administration has the benefit of maintaining better IgG trough le vels 
than monthly  IV infusions, the requirement for multiple needle insertions may  deter 
many  patients.
B.) Immunoglobulin and Hyaluronidase Treatment
The SC space is formed by  a collagen and elastin network filled with a gel- like substance, 
hyaluronan or hyaluronic acid. It is largel y responsible for the resistance to fluid flow 
through this tissue. Hy aluronidase derived from sheep or cows has been used for the last 
sixty  years to temporarily  depol ymerize the hy aluronan and facilitate SC infusions of 
fluids for re -hydration .19Recombinant human h yalunoridase (r HuPH20) is a 63 kd 
protein genetically  engineered from the sequence of the naturall y occurring human 
protein. Ittemporaril y depolymerizes the h yaluro nan, decreasing the resistance to 
fluid flow and thus facilitating infusions into the SC space. The high molecular 
weight hyaluronan has a rapid turnover and is restored within 24 to 48 h, leaving no 
observable changesiii. Weekly  infusions into cy nomolgus monkey s in doses up to 
2mg/kg (>1,000 fold higher than the Hy Qvia dose in humans )did not lead to adverse 
reactions during a follow -up of 39 weeksiv. Infusion of rHuPH20 improved absorption 
and bioavailability  of intradermall y injected IgG in rabbits, pegy lated interferon and 
infliximab in rats, and increased the rate of infusion and comfort of infusions of 
lactated Ringer’s solution in the arms of adult human volunteers 3 -to 4-fold.20
Studies investigating the effects of rHuPH20 on S C infusions of large quantities of IgG 
                                                
iiHalozyme Report Number R1005- 0551 .
iiiHalozyme Report R08014.
ivHalozyme Report R09050.
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 17of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALindogs and rabbits have been difficult to interpret due to the rapid absorption of IgG 
alone in this model . However, at higher doses of rHuPH20, bioavailability seemed to 
increase . The human SC compartment is much ti ghter than that of these animals and 
thus, human studies were required. rHuPH20 can facilitate absorption of small molecules 
such as insulin and morphine in humans ;in phase 1 trials 
rHuPH20 improved 
bioavailability  ofproteins such as infliximabvand enabled drug dispension and 
absorption at the administration site of rituximab and trastuzumab.21
In a phase 1/2 clinical study  of Hy Qvia (Stud y 160602) the average bioavailability  of the 
IgG in 7 subjects was 92%, suggesting a significant improvement compared to SC 
administration in the absence of rHuPH20.
The immunogenicity  of rHuPH20 has been monitored in a number of clinical trialsvi. No 
positive skin reactions were observed when rHuPH20 was administered to 100 healthy  
volunteers in a skin allergy  clinical trial.22  In Study  160603, a total of 13 subjects had at 
least one plasma sample that tested positive for rHuPH20- binding antibodies (positivity  
defined as a sample with a titer of ≥ 160) following HyQvia treatment. The peak of the 
observed positive titers ranged from 160 up to 81920 and have decline d during the long -
term ex tension study despite continued exposure to rHuPH20
.None of these samples 
contained neutralizing antibodies. No local or s ystemic reactions were attributed to the 
presence of rHuPH20 antibodies. Based upon data available to date, including data from 
long-term exposure in Study 160902 (63 subjects received Hy Qvia for a total number of 
187.7 subject -years ), the incidence of the for mation of anti -rHuPH20 binding antibodies 
is 18%, no neutralizing antibodies have been observed, no clinical signs or sy mptoms 
have been associated with positive anti
-rHuPH20 binding antibody  titers. In addition, 
there was no evidence of a lack of treatmen t effect when rHuPH20- binding antibodies 
were detected.
Antibodies reactive to rHuPH20 have also been identified in the normal population with a 
prevalence of approximately  5%.23No signal of associated infertility or 
autoimmune/inflammatory condition could be identified .
Non-clinical data for recombinant human hy aluronidase or antibodies to recombinant 
human hy aluronidase reveal no special hazard for humans based on conventional studies 
of safet y pharmacology, repeated dose toxicity  and developmental toxicity . Reversible 
effects on fertility  have been reported in male and fem ale guinea pigs immunized to 
produce antibodies to hyaluronidase. However, antibodies to hy aluronidase did not 
influence reproduction in mouse, rabbit, sheep, or cy nomolgus monkey .
vHalozyme Report R05109 .
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 18of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALSpecific Populations
Pregnancy , Breast Feeding, Fertility
SCIg products ha ve been shown to cross the placenta, increasingl y during the third 
trimester. Clinical experience with immunoglobulins suggests that no harmful effects on 
the course of pregnancy , or on the foetus and the neonate are to be expected.
Development and reprodu ctive toxicology  studies have been conducted with recombinant 
human hy aluronidase in mice and rabbits. No adverse effects on pregnancy and f oetal 
development were associated with anti -rHuPH20 antibodies. I n these studies, maternal 
antibodies to recombinant human hy aluronidase were transferred to offspring in utero. 
The effects of antibodies to the recombinant human hy aluronidase component of Hy Qvia 
on the human embry o or on human f oetal development are currently  unknown .
Immunoglobulins are excreted into th
e milk and may  contribute to protecting the neonate 
from pathogens which have a mucosal portal of entry .
For subjects in the EU: The safet y of HyQvia for use in human pregnancy  has not been 
established in controlled clinical tr ials and therefore should only be given with caution to 
pregnant or breastfeeding women .
For subjects in USA : HyQvia should be given to a pregnant or nursing woman only  if 
clearl y indicated. 
There are currently  no clinical safet y data for Hy Qvia on fertility  available. Clinical 
experience with immunoglobulins suggests that no harmful effects of IG10% on fertility  
are to be expected. Animal studies do not indicate direct or indirect harmful effects of 
recombinant human h yaluronidase with respect to reproductive potential at the do ses 
used for facilitating administration of IG 10%.
This pregnancy  registry  with regular assessment of anti -rHuPH20 antibodies wasa 
commitment to the Committee for Medicinal Products for Human Use (CHMP) and the 
Food and Drug Administration (FDA) . 
7.2Critical Review of Available Data
In this section, safet y, efficacy  and pharmacokinetic data obtained from clinical studies 
with Hy Qvia will be presented.
                                                                                                                                                
viHalozyme Report Number 10059 .
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 19of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL7.2.1 Clinical Study 160602
Phase I/II Determination of the Dose of Recombinant Human Hyaluronidase
Required Enabling up to 600 mg/kg Body Weight of Immune Globin Intravenous 
(Human) 10% to be Administered Subcutaneously in a Single Infusion Site in 
Subjects with Primary Immunodeficiency Disease
This study  was a prospective, open -label, non -controlled, two-arm, multicenter study  
with the aim of determining the dose of rHuPH20 necessary  to infuse a full four -
week 
dose of IGIV 10% in a single SC site with good tolerability . An infusion was defined as 
having been tolerated if it caused no more than mild loc al adverse drug reactions (ADRs) 
(eg, minimal swelling, redness, or pain) that the investigator did not assess as 
unacceptable for other medical reasons. All infusions were administered at the study  site.  
A total of 11 adult subjects (four male, seven fe male) participated in the study .  
InStudy Arm 1, four adult/adolescent subjects received only  SC infusions of IGIV 10% 
to determine tolerabilit y. After this initial assessment of tolerability, seven subjects 
(five female and two male) were enrolled in Stu dy Arm 2 for determination of tolerability  
of SC infusions as described for Study  Arm 1 and comparison of pharmacokinetic (PK) 
parameters obtained after IV and SC administration of IGIV 10% in the initial phase of 
Study  Arm 2.
The only  severe and potential ly life-threatening AE that occurred in the study  was an 
anaph ylactic reaction that was attributed to an antibiotic drug taken immediately  prior to 
onset of the s ymptoms. This serious adverse event (SAE) occurred more than 24 hours 
after an infusion and wa s not considered related to use of the study  drugs by  the 
investigator. The subject continued in the study  without further reactions. All other AEs, 
which occurred in four subjects in Study Arm 1 and six of seven subjects in Study  Arm 2, 
were non -serious l ocal AEs, of which the majorit y were mild and none were severe. 
Local AEs included infusion site ery thema, infusion site pain, infusion site edema, 
infusion site warmth, injection site pruritus, infusion site swelling, and s ymptoms 
categorized as infusion site reactions. 
The primary  safet y endpoint was the proportion of SC infusions, which were not 
interrupted or stopped due to AEs. Two SC infusions, one in each stud y arm, had to be 
interrupted due to mild infusion site pain and mild chest pain, respective ly.  In one 
subject in Study  Arm 2, the infusion rate had to be decreased due to a mild infusion site 
reaction.
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 20of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALIn conclusion, this study  of SC use of IGIV 10% facilitated by  prior injection of 
rHuPH20 y ielded initial favorable results in terms of tolerabi lity of a full four -week dose 
of IGIV 10% administered by  SC infusion in a single infusion site and in terms of 
bioavailability  of IgG after SC administration.
7.2.2 Clinical Study 160603
Efficacy, Tolerability and Pharmacokinetic Comparison of Immune Globulin 
Intravenous (Human) 10% (GAMMAGARD LIQUID, KIOVIG) Administered 
Intravenously or Subcutaneously Following Administration of Recombinant Human 
Hyaluronidase (rHuPH20) in Subjects with Primary Immunodeficiency Diseases
Study  160603 was a prospective, open -label, non- controlled, multi -center, Phase III 
study .24Thepurpose of the study  was to develop a SC treatment option for subjects with 
PIDDthat allows SC administration of GAMMAGARD LIQUID/KIOVIG at the same 
frequency  as IVadministration.  The study  consisted of two study  parts:
Study  Epoch 1: IV treatment wit h GAMMAGARD LIQUID/KIOVIG
Study  Epoch 2: SC treatment with GAMMAGARD LIQUID/KIOVIG after 
administration of 75 U/g IgG rHuPH20 at three -or four -week treatment intervals
Study  Arm 1 was comprised of subjects who previously  participated in Study  160601 and 
wished to also participate in this follow -up study ; these subjects onl y completed Study 
Epoch 2.  Study  Arm 2 comprised all other subjects; these subjects completed Study  
Epoch 1 and Study  Epoch 2.
Eight y-nine (89) subjects were enrolled in the study , of wh ich 87 were treated via both 
IVand SC routes.  Eighty -four (84) subjects completed Study  Epoch 1 and 68 subjects 
completed Study  Epoch 2.  Sixteen (16) subjects withdrew or were discontinued from the 
study , including t hree subjects who withdrew during the ramp -up period at the beginning 
of Hy Qvia treatment.  Four adults withdrew due to local pain and swelling; in two of 
these subjects, the swelling extended from the abdominal site to the genitalia, causing 
transient discomfort.  In one of the subjects, the swelling was accompanied by  erythema.  
One other subject withdrew due to a per ceived increase in infections.
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 21of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALOf the 1359 SC infusions with rHuPH 20 during the ramp-upviiperiod and Epoch 2,
90.1% were administered in the abdomen and 8.6% in the thighs.  The median duration of
individual infusions was similar or lower when GAMMAGARD LIQUID/KIOVIG was 
administered SC with rHuPH20 than for IV administration.  The percentage of subjects 
who had no infusions that required a reduction in flow rate, interruption, or had to be 
stopped due to tolerability concerns or AEs was similar between SC infusions with 
rHuPH20 (84.0%) and IV administration (88.5%).
The rate of infusions temporally  associated with sy stemic AEs was lower for SC 
administration with rHuPH20 compared to IV administration, whereas the rate of 
infusions temporally  associated with local AEs was higher for SC administration with 
rHuPH20.  The trend toward less frequent s ystemic AEs and more frequent local AEs 
during SC administration with rHuPH20 compared to IV treatment was also evident in 
the nature of AEs reported in MedDRA Preferred Terms.  Of the AEs in Epoch 1 that 
were considered b y the investigator to be possibly or probabl y related to GAMMAGARD 
LIQUID/KIOVIG, the most common were headache, chills, nausea, fatigue, py rexia, and 
vomiting.  The most common AEs possibly  or probably  related to both GAMMAGARD 
LIQUID/KIOVIG and rHuPH20 in Epoch 2 (excluding the ramp -up) were infusion site 
pain, infusion site ery thema, infusion site discomfort, headache, infusion site pruritus, 
infusion site edema, and infusion site swelling.  No severe headache was related to SC 
infusions with rHuPH20.  Adverse events possibly or probabl y related to rHuPH20 but 
not GAMMAGARD LIQUID/KIOVIG in Epoch 2 (excluding the ramp -up) included 
infusion site pain and infusion site pruritus.  The majority  of AEs were mild; very  few 
severe AEs occurred.  All SAEs were assessed as unrelated to the stud y drugs.  A 
comparison of data from the present stud y and Study  160601 demonstrated no 
appreciable differences in the median rates of AEs temporally  associated with or related 
to either or both study  drugs.
GAMMAGARD LIQUID/KIOVIG administered SC with rHuPH20 at 108% of the IV 
dose was effective in preventing bacterial infections in pediatric and adult subjects with 
PIDD.  Anal ysis of the secondary  endpoints demonstrated that GAMMAGARD 
LIQUID/KIOVIG given SC with rHuPH20 had higher bioavailabilit y as determine d by 
AUC per dose/kg than when infused SC without rHuPH20.  Compared to IV infusion, SC 
administration with rHuPH20 was administered at the same dosing interval and resulted 
in similar IgG trough levels while eliciting fewer sy stemic adverse reactions.  
                                                
viiThe treatment intervals and doses used for the initial infusions were gradually increased during the first 
weeks of treatment (referred to as the ramp -up),in order to allow  the subjects to adjust to increasing 
volumes administered SC.
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 22of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALFurthermore, SC infusion with rHuPH20 was the subjects’ preferred mode of treatment 
with GAMMAGARD LIQUID/KIOVIG.
Pharmacokinetic properties
With administration of HyQvia, peak serum IgG levels are achieved in the recipient’s 
circulation after a delay of app roximately  3 to 5 day s.
Data from the clinical trial of Hy Qvia show that serum IgG trough levels can be 
maintained by  dosing regimens of 320 to 1,000 mg/kg body  weight/4 weeks given at 
intervals of 3 -or 4-weeks.
The pharmacokinetics of Hy Qvia was evaluate d in th isphase 3 efficacy  and safet y stud y 
in 60 patients with PI DDaged 12 years and older. The pharmacokinetic results are 
presented in the table below, as compared to data for intravenous administration of 
IG10% obtained in the same study .
Table 1.
Pharmacokinetic Parameters of HyQvia Compared to
Intravenous Administration of IG 10%
Param eterHyQvia
Median (95% Cle)
N=60IGIV 10%
Median (95% Cl)
N=68
Cmaxa[g/l] 15.5 (14.5; 17.1) 21.9 (20.7; 23.9)
Cminb[g/l] 10.4 (9.4 to 11.2) 10.1 (9.5 to 10.9)
AUCcper w eek [g*days/l] 90.52 (83.8 to 98.4) 93.9 (89.1 to 102.1)
Tmaxd[days] 5.0 (3.3 to 5.1) 0.1 (0.1 to 0.1)
Apparent clearance or clearance [ml/kg/day] 1.6 (1.4 to 1.79) 1.4 (1.2 to 1.4)
Term inal half life [days] 45.3 (41.0 to 60.2) 35.7 (32.4 to 40.4)
aconcentration maximum; 
bconcentration minimum; 
carea under the curve; 
dtime to maximum concentration; 
econfidence interval
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 23of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL7.2.3 Clinical Study 160902
Long -Term Tolerability and Safety of Immune Globulin Subcutaneous (IGSC) 
Solution Administered Subcutaneously Following Administration of Recombinant 
Human Hyaluronidase (rHuPH20) in Subjects with Primary Immunodeficiency 
Diseases
The purpose of the study  was to assess the long -term safet y, tolerabilit y, and
practicability  of the SC treatment with IG, 10% facilitated with recombinant human 
hyaluronidase (rHuPH20) in subjects with PI DDwho have completed Clinical Study  
Protocol 160603. The primary  object iveof this study  was to evaluate the long -term 
tolerability  and safet y of IG , 10% given SC after an SC administration of rHuPH20 in 
subjects with PI DD .The secondary  objectives included: monitoring the long -term 
efficacy  of IG, 10% given SC after an administration of rHuPH20 in subjects with PIDD, 
evaluat ingthe effect of vary ing the dose frequency  of IG , 10% /rHuPH20 on IgG trough 
levels and assess ingthe practicability  of treating PIDD with IG , 10% given SC after an 
administration of rHuPH20 when treatment occurs in a home tr eatment environment.
In Stud y 160902, subjects beg an on the same doses of IG, 10% and rHuPH20 that were 
used for the last infusions in Study  epoch 2 of Study 160603.  In order to pursue the 
secondary  objective “effect of vary ing the dose frequency  of IG , 10% /rHuPH20 on IgG 
trough levels
”, subjects were requested to change their drug administration interval to a 
2-week drug interval (receiving a 2 -week dose) from a 4 or 3-week drug administration 
interval, provided both the subject and the investigator agree
dthat the change was
appropriate. This new treatment interval started after 3 infusions on the 4 or 3 week 
interval and was maintained for a minimum of 4months.  I t wasintended to allow for 
evaluation of whether a more frequent administration of I G, 10% leads to improved IgG 
trough levels.  After the 4month trial period, subjects could revert to their previous dose 
interval or continue on the 2 week interval, depending on the subject’s preference.
On 01 August of 2012 , the FDA requested administration of rHuPH20 drug product in all 
ongoing Hy Qvia clinical studies in the US to be suspended and patients were switched to 
treatment with KIOVIG/GAMMAGARD LIQUID only (Protocol Amendment 5 ).  
Subjects were treated with conventiona l IGIV or IGSC for 24 weeks, or,for those who 
hadanti-rHuPH20 antibody  titers ≥ 160 at the time rHuPH20 was discontinued , for 
48weeks.
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 24of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALDisposition of Subjects
Sixty -six subjects were screened for eligibility  to participate in this study. Out of the 
66 patients who rolled over from Study  160603 into 160902, 63 subjects were treated 
with I GSC, 10% with rHuPH20; 3 subjects received IGIV, 10%. Of the 63 subjects under 
IGSC, 10% with rHuPH20 treatment, 15 withdrew or were discontinued from the study ; 
48 switc hed to the Safet y Follow -
up when Protocol Amendment 5 went into effect. Of
the 15 subjects discontinued from IGSC, 10% with 
rHuPH20, 4 withdrew, 1 subject died, 
1 subject had bone marrow transplant, 6 subjects had their clinical site closed out by  
sponsor, and 3 had their site elected to exit study . Of the 48 subjects switched to the 
Safet y Follow -up period, one subject withdrew after experiencing an AE. In total, 
50subjects completed the study : 47 subjects from the Safet y Follow -up and 3 subjects 
who rece ived IGI, 10% IV or SC without rHuPH20 throughout the stud y. The majority of 
enrolled subjects were in the age range category  of 16 to <65 y ears (47 out of 66), 
followed b y 65 years and older (8 subjects), 7 subjects in the range of 12 to <16 years and 
4 subjects in the range of 2 to <12 y ears. The median age was 43.0 y ears. Of the 
66subjects who met all inclusion/exclusion criteria, 50 (75.8%) completed the study .
Extent of Exposure
IGSC, 10% with rHuPH20 was administered to 63 subjects prior to the Safet y Follow -up 
period for a median treatment duration of 669 days (range: 60- 729 day s) and a mean 
(±SD) of 565.9 ± 211.8 day s. The mean (± SD) dose received per week, per body  mass, 
was 0.156 ± 0.051 g/kg/week. Across all age groups, the median initial rate of 
IGSC, 10% infusion with rHuPH20 was 10 mL/hr (range: 5 -300) and the median 
maximum rate of infusion achieved was 300 mL/hr (range: 10- 350). Across all age 
groups and infusion intervals, a median number of 1.09 infusions/month (range: 0.3 -2.1) 
was admini stered. IGSC, 10% with rHuPH20 treatment required a median number of 
1.58 infusion sites/month (range 0.3 -4.2) across all age groups and infusion intervals. For 
the majority  of subjects in this study  (41/66; 62.1%), the 4 week -infusion interval was the 
most frequentl y followed infusion interval. The 2 week -infusion interval was the most 
frequent interval for 15/66 (22.7%) subjects and 7/66 (10.6%) subjects most frequentl y 
followed a 3- week infusion interval.
Efficacy
Analy sis of the efficacy  results in this study  indicates that rHuPH20- facilitated SC 
treatment with IGI, 10% is efficacious in the treatment of adult and pediatric subjects 
with PI DD, in terms of IgG trough levels, infection rates, and patient- related outc omes:
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 25of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALTwo validated acute serious bacterial infections ( VASBIs )occurred in 66 subjects under 
IGSC, 10% treatment with rHuPH20. The annual rate of VASBIs was statistically  
significantl y lower than the threshold specified as providing su bstantial evidence o f 
efficacy .
The point estimate for the annualized rate of all infections was 2.86 (95% CI: 2.36 -3.43) 
during IGSC, 10% with rHuPH20 treatment.
IgG trough levels maintained under IGSC, 10% with rHuPH20 treatment did not 
substantially  vary  with infusion inte rval changes and were lower with the longest 
(4-week) infusion interval (median stead y-state trough level: 10.90 g/L (2-week interval), 
12.30 g/L (3-week interval), 9.76 g/L 4-week interval). Percent change of steady -state 
trough levels was 105.90% (mean and median) for subjects who switched from a 3 -week 
to a 2-week infusion interval and a mean of 113.23% (median 112.44%) for subjects who 
switched from a 4 -week to a 2 -week infusion interval.
The point estimate for the annualized rate of day s off school/ w ork was less than 8 days 
per year. The rate of day s on antibiotics was less than 65 day s per year. The rate of 
hospitalizations was less than 1 per year and the rate of day s hospitalized, less than 1 day  
per year. The rate of acute phy sician visits due to infection or other illness was less than 
5visits per y ear.
Safety
rHuPH20 -facilitated SC treatment with IGI, 10% was safe and well tolerated by  adult and 
pediatric subjects with PID D:
No SAEs occurred that were considered b y the investigator to be related to either of the 
study  drugs. In total, 11 subjects experienced SAEs during the stud y. One subject 
experienced an SAE after study  completion.
Throughout the stud y, the proportion of infusions requiring adjustment for tolerability  
concerns or for AEs was l ow (0.1% of infusions stopped, 0.6% of infusions interrupted; 
1% infusion rate reduced). 
The most common related AEs under IGSC, 10% treatment facilitated by  rHuPH20 were 
infusion site pain, infusion site pruritus, nausea, my algia, infusion site ery thema, 
headache, fatigue, asthenia, chills, infusion site discomfort, and pain. 
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 26of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALThe rate of all AEs related to I GI, 10%, b y infusion, was 0.13 during rHuPH20 -facilitated 
IGSC, 10% treatment, and 0.22 during the Safet y Follow -up period. During rHuPH20 -
facilitated IGSC, 10% treatment, the rate of all AEs related to rHuPH20, by  infusion, was 
0.01 and the rate of all AEs related to both IGI, 10% and rHuPH20 b y infusion, was 0.06.
The rate of all causally  related AEs by  infusion was 0.20 during rHuPH20- facilitated 
IGSC, 10% treatment. The rate of all causally -related local AEs, b y infusion, was 0.10 
during rHuPH20 -facilitated IGSC, 10% treatment. During rHuPH20- facilitated IGSC, 
10% treatment, the rate of related s ystemic AEs by  infusion, including or excluding 
infections was 0. 1.
The rate of all temporall y
-associated AEs, b y infusion, was 0.28 during rHuPH20-
facilitated IGSC, 10% treatment. The rate of all temporally -associated l ocal AEs, by  
infusion, was 0.10 during rHuPH20 -facilitated IGSC, 10% treatment. During rHuPH20 -
facilitated IGSC, 10% treatment, the rate of temporally -associated s ystemic AEs by  
infusion, including infections was 0.1 8, and excluding infections 0.16. 
Throu ghout the stud y, 7.4 % of infusions were associated with one or more local AEs.
No subjects developed neutralizing antibodies in the entire duration of the follow -
up 
including data obtained in Study  160603 starting with first exposure to I GSC, 10% 
facilita ted b y rHuPH20 and in Study  160902. 
A total of 13/66 subjects had anti -rHuPH20 antibody  titers ≥ 160 in Study  160902. 
Eleven subjects had developed anti
-rHuPH20 antibody  titers ≥ 160 in Study 160603. Two 
subjects each newl y developed one anti -rHuPH20 anti body  titer of 160 in Study 160902. 
In the majority  of subjects with anti -rHuPH20 antibody  titers ≥ 160, the titers declined 
over time during IGSC, 10% with rHuPH20 treatment.
Assessment of hematology  parameters, clinical chemistry  parameters, urinaly sis and 
specific antibod y tests and viral pathogen serology did not raise an y safet y concerns with 
respect to the SC administration of IGI, 10% with rHuPH20.
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 27of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL7.2.4 Clinical Study 161101
Tolerability, Safety and Administration Mode Evaluation of rHuPH20 Facilitated 
Subcutaneous Treatment with Immune Globulin Infusion (Human), 10% in 
Subjects with Primary Immunodeficiency Diseases
This US study  was a Phase 2/3, prospective, non -controlled, multicenter study  to evaluate 
tolerability  and safet y and other pa rameters of subcutaneous treatment using Immune 
Globulin I nfusion (Human), 10% (IGI, 10% . IGI, 10% is the same product as IGIV 10%
licensed in the EU as Kiovig )with rHuPH20 in a total of approximately  60 PI DD 
subjects alread y pre -treated with immunoglobulin products (Gamunex administered IV, 
Hizentra or Privigen). PIDD patients alread y on IVor SCtreatment were enrolled and 
treated with IGI, 10% and rHuPH20 subcutaneously  with a dose/interval ramp- up of 
3weeks. The ramp- up period was Epoch 1.
The ramp -upwas followed by  Epoch 2, a 6 month period of subcutaneous IGI, 10% with 
rHuPH20 treatment:
For IV -pretreated subjects: every  3 weeks or 4 weeks, depending on the subject’s 
previous IV dosing schedule
For SC -pretreated subjects: every  3 weeks or 4 weeks, a t the discretion of 
investigator and subject
The rHuPH20 administration was discontinued as of 01 August 2012 at the request of the 
FDA.  Those subjects who did not withdraw from the study  completed the planned 
infusions using conventional IGIV or I GSC(safety follow -up period, Epoch 3) .  
A total of 37 subjects started the treatment. All but one of the subjects reached Epoch 2. 
During Epoch 2, 9 subjects withdrew. At the time when rHuPH20 administration was 
stopped, 1 subject had completed Epoch 2. The remaining 26 were switched to Epoch 3. 
During Epoch 3, 2 subjects withdrew, 24 completed Epoch 3. Thus, 25 subjects -
including the one subject who completed Epoch 2 without ever reaching Epoch 3 -
completed the stud y. 
Analy sis of the efficacy  results in thi s study  indicate that rHuPH20- facilitated SC 
treatment with IGI, 10% was efficacious in the treatment of adults and pediatric subjects 
with PI DD, in terms of IgG trough levels , infection -rates, and subject related outcomes.
Trough levels of total IgG at th e end of Epoch 2 (9.21 g/L [95%CI : 8.28 -10.25]) were 
comparable to the levels measured at screening (median 10.53 g/L [95%CI: 9.46 -11.73]). 
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 28of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALNo serious bacterial infections were reported in any  subject throughout the study . The 
point estimate for the rate of all infections per year was 2.45 for Epoch 1 and Epoch 2 
combined.
The point estimate for the rate per month of day s off either, work, school or daily  activity  
was less than 1 day /month. The rate of day s on antibiotics was less than 3 day s /month. 
No su bjects were hospitalized during the study  period and the rate of acute phy sician visit 
due to infection or other illness was less than 1 visit/month.
Analy sis of the mode of infusion was inconclusive due to the premature stop of subject 
enrollment and early termination of Epoch 2, however the following results were 
observed:   Median number of infusions per month: 2.90 in Epoch1; 1.09 in Epoch 2.  
Median number of infusion sites (needle sticks) per infusion/month: 2.90 in Epoch 1; 
1.12 in Epoch 2. Median duration of infusion less than 2h. Median maximum infusion 
rate: 240mL /h in Epoch 1; 300mL /h in Epoch 2. 
Treatment with IGI, 10% when administrated either SC with rHuPH20 (Epochs 1 and 2) 
or SC without rHuPH20 or IV (Epoch
3) was safe and well tolerated. No SAEs occurred 
that were considered b y the investigator to be related to either of the stud y drugs.
During Epoch 1 and Epoch 2 combined, 59 related sy stemic AEs occurred. The rate of 
related s ystemic AEs/infusion, excluding infections (primary  outcome) was 0.326 
(95%CI : 0.186 -0.522) and the rate per number of subjects was 37.8% (14/37), for Epochs 
1 and 2 combined.   The rate per infusion of local AEs (including infections) related to 
IGI, 10% was 0.066 in Epoch 1, 0.028 in Epoch 2 and 0.006 in Epoch 3. The rate of 
local AEs related to rHuPH20 per infusion was 0.039 in Epoch 1 and 0.038 in Epoch 2. 
The rate of local AEs related to both rHuPH20 and IGI, 10% per infusion was 0.776 in 
Epoch 1 and 0.745 in Epoch 2.
According to MedDRA preferred term classification, the most common AEs related to 
IGI, 10% with rHuPH20 in both Epoch 1 and Epoch 2 were “infusion site pain”, 
“infusion site ery thema”, a nd “infusion site swelling”.
No patient developed neutralizing anti
-rHuPH20 antibodies in the course of the study .
Assessment of hematology  parameters, clinical chemistry  parameters, urinaly sis did not 
raise an y safety concerns with respect to the SC admin istration of I GI, 10% with 
rHuPH20.
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 29of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL7.2.5 HyQvia PASS 161302
Non-Interventional Post- Authorization Safety Study on the Long -Term Safety of 
HyQvia in Subjects treated with HyQvia
This is a non- interventional, prospective, uncontrolled, multi -center, open -label, p ost-
authorization safet y study in the European Economic Area. The Post-Authorization 
Safet y Surveillance (PASS )was a request of the CHMP in the course of the Hy Qvia 
Marketing Authorization Procedure. 
The purpose of the study  is to acquire additional data (including the assessment of anti-
rHuPH20 antibodies) on the long -term safety  of Hy Qvia and to assess the prescribed 
treatment regimens and treatment administration in routine clinical practice.
The primary  objective is to collect and assess safety  data, in particular the occurrence of 
long-term changes in incidence and severity  of related adverse events in patients treated 
with Hy Qvia. 
Secondary  objectives are to collect data on the prescribed treatment regimen, anti -
rHuPH20 antibodies and, as available, other laboratory  safety  assessments, total IgG, 
further safet y assessments that are obtained during the routine clinical management of the 
subjects, treatment administration, and health
-related quality  of life and health resource 
use assessments (optional ).
Adult patients ( ≥ 18 y ears) who have been prescribed treatment with Hy Qvia are
enrolled. Treatment regimens areprescribed at the discretion of the attending phy sician in 
accordance with routine clinical practice. Visits to the investigator and all othe r medical 
care are performed as is standard for the site and for the subject´s healthcare. In addition, 
however, the subject isrequested to have additional blood samples drawn at the time of 
routine laboratory  assessments approximately  every  3 months, but no more often than 
4times a y ear, for the measurement of anti-rHuPH20 antibodies.
The overall duration of the study  is approximately  six y ears from stud y initiation (ie, first 
subject enrolled) to stud y completion (ie , last subject last visit). The recruitment period is 
expected to be approximately  three y ears. E nrollment started in Q3/ 2014.The subject 
participation period is approximately  three to six y ears from enrollment to subject 
completion (ie, last study visit) , depending on the time point of enrollment, unless 
prematurel y discontinued. I t is anticipated that approximately  80 to 120 subjects will be 
eligible for enrollment in this study .
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 30of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL7.2.6 HYQ VIA Study 161406
Non-Interventional Post- Marketing Safety Study on the Long -Term Safety of 
HYQVIA (Global)
This planned prospective, uncontrolled, multi- center, open -label, post -HYQVIA 
marketing authorization surveillance stud y with assessment of anti-rHuPH20 antibodies 
was agreed upon with the Food and Drug Administration (FDA) in the course of the 
HYQVIA Biologic License review and approval process. 
The purpose of the study  is to acquire additional data (including the assessment of anti -
rHuPH20 antibodies) on the long -term safety  of HYQVIA and to assess the prescribed 
treatment regimens and treatment administration in a total of 250 adult evaluable subjects 
with PI DD under routine clinical conditions .Further data shall be collected in subjects 
with an anti -rHuPH20 antibody  titer ≥ 160.
The primary  objective is to collect an d assess safety  data, in particular the occurrence of 
long-term changes in incidence and severity  of related adverse events in patients treated 
with HYQVIA.
Secondary  objectives are to collect data on anti -rHuPH20 antibodies and, as available, 
other labora tory safety  assessments, total IgG, further safet y assessments that are 
obtained during the routine clinical management of the subjects, the prescribed treatment 
regimen, treatment administration, health- related quality  of life and health resource use 
assessments.
It is planned to have FSI in Q4/2015 .
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 31of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL8.RESEARCH QUESTION AN D OBJECTIVES
8.1Research Question
The purpose of th isregistry  is to acquire safet y data (including assessment of anti-
rHuPH20 antibodies), regarding the course and outcome of pregnancy  inwomen ever 
treated with Hy Qvia . Development of the fetus/infant at birth and for the first 2 y ears will 
also be followed.
8.2Primary Objective
The primary  objective of the study  is to collect and assess clinical safet y data regarding 
the possible effects of H yQvia on the 
course and outcome of pregnancy , and on the 
growth and development of the fetus/ infant .
8.3 Secondary Objectives
8.3.1 Safety
The secondary  objective of the study  is to collect any  laboratory  safet y data and 
additional safet y assessments obtained during the clinical management of the pregnancy  
or in the evaluation of the fetus 
in utero and the infant post partum .
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 32of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL9.RESEARCH METHODS
9.1Study Design
This study  is a non- interventional, prospective, uncontrolled, two-arm, open -label ,
multicenter post-authorization pregnancy  registry  of women ever treated with HyQvia.
The overall study  design is illustrated in Figure 1.
Subjects who prior to th e study  received Hy Qvia and at enrollment receive a licensed 
human normal immunoglobulin other than Hy Qvia or an alternative treatment during the 
study  will be assigned to Study  Arm 1 (Alternative Product Arm); subjects in countries, 
where Hy Qvia treatment during pregnancy  is not indicated, should be enrolled in this 
arm. Subjects who continue treatment with Hy Qvia during pregnancy  will be followed in 
Study  Arm 2 (Hy Qvia Arm )
.
The registry  is designed according to the CHMP Guideline on the exposure to medicinal 
products during pregnancy: Need for post -authoris ation data25;and theU.S. Department 
of Health and Human Services Guidance for Industry : Establishing Pregnancy  Exposure 
Registries .26
Female patients being treated with Hy Qvia willnotify  their 
treating physician (for 
example their immunologist) immediatel y of the pregnancy . 
Once Baxalta is notified, details will be provided regarding the registry  and how to enroll.
Study  Arm 1 (Alternative Product Arm): The subject stops Hy Qvia treatment (if the 
subject is still treated) and a licensed human normal immunoglobuli n other than Hy Qvia 
for IV or SC infusion or an alternative treatment will be administered, as determined b y 
the phy sician. Subjects in countries, where Hy Qvia treatment during pregnancy  is not 
indicated, should be enrolled in Study  Arm 1. The date and ges
tational age will be 
collected for an y subject in the Alternative Product Arm who restarts HyQv ia. Details 
about the administration of Hy Qvia should be recorded on the HyQvia treatment CRF.
Study  Arm 2 (Hy Qvia Arm): Subject continues to receive HyQvia , according to her 
treatment regimen. 
The data f or the registry  will be derived from several medical specialists (such as 
immunologist, gy necologist, obstetrician, pediatrician). The specialist responsible for the 
pregnant woman´s H yQviatreatment and/or the treatment of her underl ying disease will 
be responsible for data collection and CRF completion.
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 33of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALData will be collected according to the standard of care in the region. After enroll ment in 
the registry  by signing the appropriate ICF, the pregnant subje ct will return to her
physicians as she normally  would as part of routine medical practice. There will be no 
required predefined visits, medical tests, laboratory tests and procedures during the 
course of the registry , except for the assessment of antibodies to rHuPH20. 
Approximately  every  3 months ,the 
pregnant subject will be invited to have a blood 
sample taken for the measurement of anti-rHuPH20 
antibodies. For subjects with an anti -
rHuPH20 antibody  titer ≥ 10,000, antibody  characterization will be performed. Data of 
the occurrence of AEs, compli cations of the pregnancy , and f etal growth and 
development will be recorded on the CRF, if data is available.
After delivery /end of pregnancy data on the outcome of the pregnancy will be collected, 
if available. 
The infant will be followed up for two years to collect safet y data. Approximately every 
6±2 months (as part of routine medical practice) the infant and 
thelegal representative (s)
will be invited to return to the pediatrician /lead phy sician to record assessments 
according to T able 3and Table 5.
The pediatrician /lead ph ysician will record data of the development and growth of the 
infant on the appropriate CRFs , if 
data is available .
9.1.1 Primary Endpoint
The primary  endpoint is the incidence of all SAEs (expectant mother and infant) .
9.1.2 Secondary Endpoints
9.1.2.1 Safety
1.Incidence of non- serious AEs, related and not- related to Hy Qvia/Human normal 
immunoglobulin or alternative treatment (expectant mother and infant)
2.
Incidence of local/immunologic AEs including skin changes (such as: local 
erythema, local pruritus, induration, nodules) (expectant mother)
3.Development of anti-rHuPH20 antibodies (rHuPH20 binding and neutralizing 
antibodies) ( expectant mother )
4. C omplications of pregnancy
5.Fetal growth/development
6. O utcome of pregna ncy
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 34of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL7.Neonatal assessment
8.Status of the infant at birth 
9. Growth measurement and charts for the infant, if available
10.Development milestones determined b y standard test methods, for each region, if 
available
9.2 Setting
In order to anal yseall data which may  become available, no exclusion criteria have been 
defined for this registry . Visits to the investigator (for example immunologist) ,and all 
other medical care ,will be performed as is standard for the site and for the subject’s 
healthca re. However ,the pregnant subject will be invited to return approximately  every  3 
months to the site for blood samples to be taken to assess anti-rHuPH20 antibodies, as 
requested b y the CHMP and the FDA . 
Should a phy sician retrospectivel y (ie, at a more a dvanced stage of the pregnancy )
become aware of a patient who could have been included in this registry , then the 
physician should include this patient and the patient’s data should be entered 
retrospectively (as available) , if the patient provides informe d consent.
9.2.1 Medicinal Product(s)
As soon as the 
patient becomes aware of the pregnancy ,sheshould inform the treating 
physician. According to her treatment (see Section 9.1),the subject enters the study in 
one of the following 2 Study  Arms
:
Study Arm 1 ( Alternat ive Product Arm): Subject swho stop treatment with Hy Qvia will 
be followed in Study  Arm 1. The treating physician of the pregnant woman prescribe sa 
licensed human normal immunoglobulin other than Hy Qvia for IVor SCinfusion or an 
alternative treatment , at 
his/her discretion .
Study  Arm 2 (Hy Qvia Arm): Subject s who continue treatment with HyQvia ac cording to 
their treatment regimen will be followed in Study Arm 2.
Product information such as dosage, dosage regimen, a dministration, packaging, labeling, 
and storage for th e medicinal product s are described in the respective package 
insert/SPC .
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 35of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL9.2.2 Duration of Study Period(s) and Subject Participation
The overall duration of the study  is approximately  6 yearsfrom study  initiation ( Registry  
ready to enroll ) to study  completion (ie, end of data collection ). The enrollment period is 
expected to be 3 years.
The participation period for the pregnant woman is from enrollment to delivery /end of 
pregnancy . The participation period for the infant is from enrollment until the age of 
2years to assess the development , unless prematurely  discontinued.
9.2.3 Subject S election Criteria
9.2.3.1
Inclusion Criteria
Subjects who meet ALL of the following criteria are eligible for this stud y:
For the expectant mother only : Subject became pregnant during or after treatment 
with Hy Qvia
Subject /subje ct’s legall y authorized representative is willing to sign ICF
9.2.3.2 Exclusion Criteria
There are no applicable Exclusion Criteria for this registry .
9.2.4 Informed Consent and Enrollment
Any patient who provides informed consent (ie , signs and dates the informed consent
form and , if applica ble,the assent form) is considered enrolled in the stud y.
9.2.5 Subject Identification Code
The following series of numbers will comprise the Subject I dentification Code ( SIC): 
protocol identifier (eg, 1613 01) to be provided b y the MAH /MAH’s representative(s) , 
3-digit study  site number (eg, 002) to be provided by  the MAH /MAH’s representative(s) , 
and 3 -digit subject number (eg, 003) reflecting the order of enrollment (ie , signing the 
informed consent form). For example, the third subject who signed an informed c onsent 
form at study  site 02 will be identified as Subject 161301- 020003. All study  documents 
(eg, CRFs, clinical documentation, sample containers, etc.) will be identified with the 
SIC. Additionally , a uniquely  coded SIC(s) is permitted as long as it does not contain a 
combination of information that allows identification of a subject (eg, collection of a 
subject’s initials and birth date would not be permitted), in compliance with laws 
governing data privacy .The expectant mother and the infant will be en rolled 
individually , each with a unique SIC
.
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 36of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALSubject I dentification Codes identify ing matching mother -infant pairs will be provided in 
the final Clinical Study  Report. The infant’s CRF includes a field titled 
‘Mother ’sSubject ID’. The re will be a manual r eview of the CRF to match the mother -
infant pair.
9.2.6 Screening and Study Visits
The study  site is responsible for maintaining an enrollment/screening log that includes all 
subjects enrolled. The log also will serve to document the reason for screening failure. 
All screening data will be collected and reported in CRFs, regardless of sc reening 
outcome. If a subject is re -screened, the End of Study  CRF should be completed, and a 
new ICF, new SI C and new CRF are required for that subject.
For subjects in USA : The site should also maintain patient identifier information (such as 
name of the patient, name of person reporting the pregnancy , date of initial contact with 
the reporter about the registry  and dates of follow- up contacts, telephone number of the 
reporter) , as recommended by  the FDA guidance .26
The ove rall study  design is illustrated in Figure 1. Details on the procedures and 
assessments 
to be performed at each study  visit, including screening, can be found in 
Table 2to Table 5. 
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 37of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALFigure 1.
Study Design for Baxalta Clinical Study 
161301
Note: Procedures and assessments are performed according to the routine standard at the site, and are 
documented as available (with the exception of Informed Consent, Eligibility and anti -rHuP H20 
antibodies assessments).Stop HyQvia, if still treated:
Study Arm 1
(Alternative Product Arm) 
Pregnancy
Expectant Mother:
Treatment with alternative licensed human 
norm al immunoglobulin /alternative 
treatment and standard medical care
-Assessment of safety data and rHu PH20
antibodies (approx. every 3 months )
Fetus:
-Observation of fetal growth and 
development
Delivery/End of Pregnancy
Record outcome
Mother /Wom an 
End of Study
At next visit to the 
lead physician, (e.g., 
the immunologist )
should be w ithin 6 
months of
Delivery/End of 
PregnancyInfant
-Status at birth
-Record grow th 
measurements and 
development 
milestones, if 
available , 
for 24 monthsPregnancy during or after treatment with HyQvia confirmed
End of StudyEnrollment in study 161301 Continuation of HyQvia treatment:
Study Arm 2
(HyQvia Arm)
Enrollment in study 161301 
Pregnancy
Expectant Mother:
Treatment with HyQvia and standard medical 
care
-Assessment of safety data and rHu PH20
antibodies (approx. every 3 months )
Fetus:
-Observation of fetal growth and 
development
Delivery/End of Pregnancy
Record outcome
Mother /Wom an 
End of Study
At next visit to the 
lead physician, (e.g., 
the immunologist )
should be w ithin 6 
months of
Delivery/End of 
PregnancyInfant
-Status at birth
-Record grow th 
measurements and 
development 
milestones, if 
available , 
for 24 months
End of Study
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 38of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALTable 2.
Schedule of Study Procedures and Assessments for the Expectant 
Mother
Procedures/
AssessmentsScreening 
VisitInterval Study VisitsStudy Completion/ 
Termination
VisitcPregnancy
Approx. every 
3 monthsDelivery/ 
End of 
Pregnancy
Informed Consent aX
Eligibility Criteria X
Medical History/ Interval Medical 
HistoryX X X X
Medications X X X X
Non-drug Therapies X X X X
Physical Exam X X X X
Vital Signs X X X X
HyQvia Treatment Regimen/
Administrationd, if applicableX X X X
Adverse Events X X X
Neonatal/fetal information X X X
Ultrasound of fetus X X
Laboratories bX X X X
aOccurs at enrollment (prior to any study -specific procedure).
bLaboratory results ,if available, see Table4.
cStudy Completion Visit to take place after delivery/end of pregnancy at the next visit to lead physician ,
(e.g., the immu nologist )(should be w ithin 6 months of delivery/end of Pregnancy) . Term ination visit 
applies to cases of withdraw al or discontinuation.
dThe subject’s treatment regimen will be prescribed at the discretion of the attending physician in 
accordance w ith routine clinical practice. Changes to the treatment regimen, including the reason for the 
change, will also be collected. If treatment is adm inistered at the site and a hometreatment record is 
available then infusion administration details such as: maximum infusion rate, infusion volume, number 
and location of infusion sites, date of infusion and infusion start and stop time, and batch number should 
be collected. Product administrations may or may not coincide w ith site visits.
Note: Procedures and assessments are performed according to the routine standard at the site, and are 
documented as available (with the exception of Informed Consent)
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 39of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALTable 3.
Schedule of Study Procedures and Assessments for the 
Infant
Procedures/
AssessmentsInterval Study Visits Study Completion/ 
Termination
VisitcBirth Approx. Month 6, 12, 18 
(each visit ± 2 m onths)
Informed Consent aX
Status at Birth X
Interval Medical History X X
Medications X X X
Non-drug Therapie s X X X
Physical Exam X X X
Vital Signs X X X
Adverse Events X X X
Laboratories bX X X
Assessment of growth and 
DevelopmentX X
aOccurs at enrollment (prior to any study -specific procedure).
bLaboratory results ,if available , see Table5
cTerm ination visit  applies to cases of withdrawal or discontinuation.
Table 4.
Clinical Laboratory Assessments for the Expectant 
Mother, if available
Assessments
Screening 
VisitInterval 
Study Visits Study 
Completion/ 
Termination
Visit bPregnancy
Approx. every 
3 monthsDelivery/ 
End of 
Pregnancy
Hem atology X X X X
Clinical Chemistry X X X X
Urinalysis X X X X
Anti-rHuPH20 antibodiescX X X
Antenatal diagnostic procedure aX X
aProcedures such as serology tests (eg ,rubella, toxoplasmosis), serum markers (AFP, other), CVS, 
Amniocentesis
bStudy Completion Visit to take place after delivery/end of pregnancy a t the next visit to the lead
physician , (e.g., the immunologist )(should be w ithin 6 months of delivery/end of Pregnancy) . 
Term ination visit applies to cases of withdrawal or discontinuation.
CFor subjects w ithbinding anti -rHuPH20 antibod ies of a titerof ≥ 160, assessments for neutralizing 
antibodies will also be done . For subjects with an anti -rHuPH20 antibody titer ≥10,000, antibody 
characterization wil l be performed in addition (see Section 9.3.4.1 ).
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 40of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALTable 5.
Clinical Laboratory Assessments for the Infant, if available
Assessments Interval 
Study Visits Study Completion/ 
Termination
VisitaBirthApprox Month  6,  12, 18 
(each visit ±2 months)
Hem atology X X X
Clinical Chemistry X X X
Urinalysis X X X
aTerm ination visit  applies to cases of withdrawal or discontinuation.
9.2.7 Subject Withdrawal and Discontinuation
Any subject may  voluntarily  withdraw (ie , reduce the degree of participation in the study ) 
consent for continued participation and data collection. The reason for withdrawal will be 
recorded on the End of Study  CRF. The data collected on withdrawn subjects will be 
used in the anal ysis and includ ed in the non-interventional study  report.
Discontinuation (ie, complete withdrawal from study  participation) may  be due to 
dropout (ie, active discontinuation by  subject) or loss to follow -up (ie, discontinuation by  
subject without notice or action). 
9.2.8 Study Stopping Rules
Stopping rules will not be established for this study as the pregn ant 
subjects will be 
treated with a licensed human normal immunoglobulin or an alternative treatment , 
according to the routine standard at the stud y site, for the duration of the study . The 
study  will be terminated by  the sponsor if no subjects are enrolled during the predefined 
enrollment period.
9.3Variables
9.3.1 Safety Variables
9.3.1.1 Variables for Pregnancy ,Pregnancy Outcome , and Infant Follow -up
All d ata with the exception of anti-rHuPH20 antibodies, will be collected as available 
from routine clinical practice. 
For subjects in USA : The source of the data (such as: obstetrician, p ediatri cian,pregnant 
woman/mother) should be captured
,and the date when the data arereceived for the
registry ,if available , as recommended b y the FDA guidance .26
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 41of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL1. During pregnancy  the outcome of the ultrasound examination (ultrasound  reports) 
of the fetusshould be recorded to assess the fetal g rowth and development. The 
result should be assessed (for example normal or abnormal )and a short description 
of the status should be added.
2. Pregnancy  outcome .After delivery /end of pregnancy the following neonatal /fetal
information should be recorded initially :
Data on delivery  including mode of delivery , labour/delivery  complications 
(eg,fetal distress, amniotic fluid abnormal) and abnormal placenta
Outcome of pregnancy  and date [induced or spontaneous termination, fetal 
death (ectopic, miscarriage, molar pregnancy ), live birth normal/abnormal, 
other ]
Date of birth
Gestational age at birth , Maturity  assessment/Dy smaturity
Gender of neonate
Results of neonatal assessment including:
Weight, length and head circumference at birth
Conditions at birth incl uding Apgar scores at 1 and 5 minutes, need for 
resuscitation, admission inintensive care unit
Malformation/anomalies diagnosed at birth
Neonatal illness, hospitalization, drug therapies
3. Infant follow -up.At inter val study  visits, infant follow -up information should be 
collected for the following points: 
Malformation/anomalies diagnosed since initial report
Growth measurement and charts
Developmental assessment such as developmental milestones
Infant illnesses, hospitalizations, drug ther apies, breastfeeding
4. In case of elective termination, spontaneous abortion and late fetal death the 
following fetal data should be collected:
Reason for termination
Gestational age at termination
Results of phy sical examination (gender, external anomalies) and pathology
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 42of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL9.3.2 Medical History, Interval Medical History, Medication s, and Non -Drug 
Therap ies
At screening, the subject’s medical history  will be described for the following body  
systems including severity (mild, moderate, or severe as defined in Section 11.2.4) or 
surgery  and start and end dates, if known: ey
es, ears, nose, and throat; respiratory ; 
cardiovascular; g astrointestinal; musculoskeletal; neurological /psychiatric ; endocrine; 
hematopoietic/lymphatic; dermatological; and genitourinary /obstetrical .Furthermore ,
data on the obstetrical history  of the mother should be recorded, including number of 
previous pregnancies and outcome, previous mater nal pregnancy  complications, previous 
fetal/neonatal abnormalities ,and,type and history of subfertility .
For the maternal medical history ,risk factors for adverse pregnancy outcomes (e.g.
hypertension, diabetes, seizure disorder, thy roid disorder )shoul d be evaluated. Also the 
exposure to other teratogens 
(e.g. infections, medications, environmental factors) should 
be recorded, if available.
Data collected on the family  history  of the mother should include the history  of 
congenital abnormality , psychomotor retardation in the family  and the consanguinit y 
between parents. For the current pregnancy ,the following data should be collected:
Date of last menstrual period (L MP)
Estimated date of delivery
Weight gain during pregnancy  
Number of fetuses
Treatment for infertility  (specify )
Recreational drug use, eg ,tobacco, alcohol, illicit drugs (specify  amount and if and 
when stopped during pregnancy )
Complications during pregnancy  and date (including an y adverse drug reactions)
Disease course(s) during pregnancy  and an y complications
The following data for the treatment with HyQvia should be collected on the Hy Qvia 
CRF: Indication for which Hy Qvia was administered, start date of treatment,  regimen,
treatment interval, date and dose of the last infusion for Study  Arm 1 and for ongoing 
infusions in Study  Arm 2 .
All medications taken and non- drug therapies received from 6 months before enrollment
until completion/termination will be recorded on the concomitant medications and non -
drug therapies CRFs. Furthermore, for subjects in Study  Arm 1 (Alternat ive Product 
Arm) the data of the licensed human normal immunoglobulin /alternative treatment
prescribed after stop of Hy Qvia will be collected on these CRFs. 
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 43of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL9.3.3 Physical Examinations
At screening and subsequent study  visits (as described in Table 2and Table 3), a ph ysical 
examination should 
be performed on the following bod y systems being described as 
normal or abnormal: general appearance, head and neck, ey es and ears, nose and throat, 
chest, lungs, heart, abdomen, extremities and joints, ly mph nodes, skin, and neurological. 
At screening, if an abnormal condition is detected, the condition will be described on the 
medical history  CRF. At study  visits, if a new abnormal or worsened abnormal pre -
existing condition is detected, the condition will be described on the AE CRF. If the 
abnormal value was not deemed an AE because it was due to an error, due to a pre -
existing disease (described in Section 11.2.7), not clinically  significant, a sy mptom of a 
new/worsened condition alread y recorded as an AE, or due to another issue that will be 
specified, the investigator will record the justification on the source record.
9.3.4 Clinical Laboratory Parameters
The protocol does not mandate an y laboratory  testing .However the pregnant subject will 
be invited to provide blood samples for the assessment of anti-rHuPH20 antibodies , (see 
Section 9.3.4.1 andTable 4), based on the request of the CHMP and the FDA . 
Assessment of hematology , clinical chemistry ,urinaly sis and antenatal parameters will be 
done at local laboratories , according to standard of care of the study  site or at the 
discretion of the investigator.
The investigator’s assessment of each laboratory  value will be recorded on the 
appropriate form. For each abnormal laboratory  value, the investigator will determine 
whether the value is clinically  significant or not. For clinicall y significant values, the 
investigator will indicate if the value constitutes a new AE (see definition in Section 11.1, 
and record the sign, s ymptom, or medical diagnosis on the AE CRF)
;is a symptom of, or 
related to ,a previousl y recorded AE; is due to a preexisting disease (described in 
Section 11.2.7) ;or was due to another issue that will be specified. If the abnormal value 
was not clinicall y significant, the investigator will indicate the reason, ie, because it is 
due to a preexisting disease, due to a lab error, or due to another issue that will be 
s
pecified. However, additional tests and other evaluations required to establish the 
significance or etiology  of an abnormal value, or to monitor the course of an AE should 
be obtained when clinically  indicated. An y abnormal value that persists should be 
followed at the discretion of the investigator.
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 44of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL9.3.4.1 rHuPH20 antibodies
Anti- rHuPH20 anti bodies should be collected as indicated in Table 4. For subjects with 
an anti -rHuPH20 antibody  titer 
≥ 160 also neutralizing antibodies will be measured. In 
addition, characterization of antibodies will be performed in subjects who test posi tive for 
anti-rHuPH20 antibodies at a titer of ≥ 10,000. Characterization will include neutralizing 
antibodies and antibodies cross reacting to Hy al 1, 2 and 4.
Testing will be done in a central laboratory  selected by  the MAH/MAH´s 
representative(s) . Resul ts for anti -rHuPH20 antibodies and antibod y characterization, if 
applicable, will be forwarded by  the central laboratory  to both the investigator and the 
MAH/MAH´s representative(s) and will not need to be transcribed into the CRF by  the 
investigator.
9.3.4.2 Hema tology and Clinical Chemistry
Results from the assessment of hematology  and clinical chemistry ,if routinely  performed 
during clinical practice or indicated based on the clinical judgement of the treating 
physician, will be collected as indicated in Table 4and Table 5.
Data collected from the hematology  panel (if available) will consist of complete blood 
count [hemoglobin, hematocrit, ery throcy tes (ie, red blood cell count), and leukocy tes (ie, 
white blood cell count)] with differential (ie, basophils, eosinophils, ly mphocy tes, 
monocy tes, neutrophils) and plat elet counts. 
Data collected from the clinical chemistry  panel (if available) will consist of sodium, 
potassium, chloride, bicarbonate, protein, albumin, alanine aminotransferase, bilirubin, 
alkaline phosphatase, blood urea nitrogen, creatinine, and glucos e. 
9.3.4.3 Urinalysis
Data collected from the urinaly sis (if available) should include specific gravity , pH, 
protein, glucose, ketones, bilirubin, urobilinogen, blood, nitrite, leukocy te esterase, and 
microscopic examination.
9.3.4.4 Antenatal Diagnostics
For antenatal d
iagnostic ,data on the following tests and procedures should be collected
(if available) : Results of serology  tests (eg ,rubella, toxoplasmosis), serum markers (AFP, 
other), Chorionic villi biopsy  (CVS) andAmniocentesis , fetal ultrasound or other 
imaging (see also Section 9.3.1.1) .
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 45of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL9.3.4.5 Biobanking
Blood samples for anti-rHuPH20 antibodies that remain after study  testing is done may  
be stored and used for additional testing (eg, further evaluation of an abnormal test or an 
AE). Samples will be stored in a coded form for a maximum of 2 y ears after the final 
study  report has been completed and ,subsequently ,will be destro yed.
9.3.5 Vital Signs
Vital signs of the subjec t (expectant mother and infant) will include body  temperature 
(°Cor °F) , respiratory  rate (breaths/min), pulse rate (beats/min) ,sitting (for the expectant 
mother ) systolic and diastolic blood pressure (mmHg) , height /length (in or cm) and 
weight (lb or kg) .The values
will be reported as available .
Vital signs will be recorded on the CRF. For each abnormal vital sign value, the 
investigator will determine whether or not to report an AE (see definition in Section 11.1
and record the medical diagnosis (preferabl y), symptom, or sign on the AE CRF ). 
Additional tests and other evaluations required to establish the significance or etiology  of 
an abnormal value ,or to monitor the course of an AE should be obtained when clinicall y 
indicated. An y abnormal value that persists should be followed at the discretion of the 
investigator.
9.3.6 Subject Completion/Discontinuation
A subject is considered to have completed the stu dy when she /heceases active 
participation in the study  because the subject has, or is presumed to have, completed the
study  according to the protocol.
Reasons for completion/discontinuation will be reported on the 
Completion/Discontinuation CRF, including
: completed, screen failure, adverse event 
(eg, death), discontinuation by  subject (eg, lost to follow -up [defined as 3 documented 
unsuccessful attempts to contact the subject], dropout), phy sician decision (eg,  
progressive disease, non- compliance with pr otocol violation(s), recovery ), study  
terminated b y MAH , orother (reason to be specified by  the investigator, eg, technical 
problems). Regardless of the reason, all data available for the subject up to the time of 
completion/discontinuation should be reco rded on the appropriate CRF. 
The reason for discontinuation will be recorded on the CRF, and data collected up to the 
time of discontinuation will be used in the anal ysis and included in the clinical study  
report. 
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 46of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALIn the event of subject discontinuation due to an AE, clinical and/or laboratory  
investigations performed as part of the evaluation of the event ,will take place under the 
direction of the investigator and will be reported to the MAH /MAH’s representative(s) .
Details of the outcome may  be reporte d to the appropriate regulatory  authorities by  the 
responsible part y.
9.4Data S ources
9.4.1 Source Data
Source data are defined as all information in original records and certified copies of 
original records of clinical findings, observations, or other activities in a clinical trial that 
are necessary  for the reconstruction and evaluation of the trial. Source data are contained 
in source documents (orig inal records or certified copies), which may  be in paper and/or 
electronic format. Source data for this study  comprise the following: hospital records, 
medical records, clinical and office charts, laboratory  notes, memoranda, evaluation 
checklists, outcome s reported b y subjects, recorded data from automated instruments, 
subject files, and records kept at the laboratories , and at medico- technical departments 
involved in the study .
For additional information on study  documentation and CRFs refer to Section 9.6.1 . 
9.5Study Size
There is no pre -specified minimum sample size for this registry . All women ever treated 
with HyQvia who bec ome pregnant will be requested to participate in the registry  by the 
MAH. Every effort will be made to iden tify and include subjects in this registry . 
Furthermore ph ysicians treating patients with HyQvia will be informe d of the possible 
enrollment in this registry. The purpose of the registry  and the possibility of participation 
isincluded in the package insert/ Summary  of Product Characteristics of the respective 
country .
9.6Data Management
9.6.1 Data Collection Methods
The investigator will maintain complete and accurate s tudy documentation in a separate 
file. Study  documentation may  includ e information defined as „source data“ (see 
Section 9.4.1) records detailing the progress of the study  for each subject, signed 
informed consent forms, correspondence with the EC and the study  
monitor/ MAH /MAH’s representative(s) , enrollment and screening information, CRFs, 
SAE reports (SAERs) , laboratory  reports ( if applicable), and data clarifications requested 
by the 
MAH /MAH’s representative(s) .
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 47of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALThe investigator will comply  with the procedures for data recording and reporting. Any  
corrections to paper study  documentation must be performed as follows: 1) the first entry  
will be crossed out entirely , remaining legible; and 2) each correction must be dated and 
initialed by  the person correcting the entry ; the use of correction fluid and erasing are 
prohibited.
The investigator is responsible for the procurement of d ata and for the quality  of data 
recorded on the CRFs. CRFs will be provided in electronic form. 
Only authorized study  site personnel will record or change data on the CRFs. All data 
with the exception of adverse events (see Serious and Non -serious Adverse Event 
Reporting, Page 2) should preferabl y be entered on the CRFs during the study  visit or 
within 10 
business day s. Changes to a CRF will require documentation of the reason for 
each change. The handling of data b y the MAH /MAH’s representative(s) , including data 
quality  assurance, will comply  with regulatory  guidelines and the standard operating 
procedures of the MAH /MAH’s representative(s) . Data management and control 
processes specific to the study  will be described in the data management plan (see 
Section 14.1).
9.6.2 Software
Electronic Data Capture/Collection ( EDC )with the standard data management software 
of the Contract Research Organization ( CRO ) selected is used.
The software for the data anal ysis is the standard data anal ysis software of the CRO 
selected.
9.7Data Analysis
9.7.1
Datasets and Analysis Cohorts
Due to the small number of subjects expected in this study , all subjects will be anal yzed 
according to the Stud y Arm 1 and 2, and together. If the treatment of the subject is 
changed in the course of the study, the subject will continue to be followed in the study  
arm assigned initially ,for the remaining observation period.
9.7.2 Handling of Missing, Unused, and Spurious Data
Statistical techniques will not be used to identify  and exclude any  observations as outliers 
from the anal yses. If an y data is considered spurious, eg ,for lack of biological 
plausibility , it will be documented to include the re ason for exclusion and the anal yses 
from which the data points were excluded.
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 48of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL9.7.3 Methods of Analysis
Statistical analy ses and data display s will be descriptive. Data from all enrolled subjects 
will be included in the analy ses. Retrospective reports and prospective reports are clearl y 
labeled
.It will be considered to anal yzethem separatel y.Retrospective data should be 
recorded on the Medical History  CRF. Details about the anal ysis of retrospective data 
will be provided in the Statistical Anal ysis Plan.
All SAEs, non -serious AEs and other t ypes of safety data will be categorized according 
to MedDRA sy stem organ class (SOC) and preferred term ,as far as possible. 
Concomitant medications and non
-drug therapies will be recorded and tabulated. Tables 
will be prepared to list for each SAE, non -serious AE and other t ype of safety data ,the 
number of events/data , and the number of subjects who experi enced one or more events. 
Outcome measures regarding pregnancy  loss, stillbirth, and congenital abnormalities ,will 
be compared to published data for the region and ,if known, for the specific patient 
population. Growth and development of the infant will b e compared to growth 
parameters for the specific region as appropriate , if available, or else to standard 
published charts. 
9.7.3.1 Primary Endpoint
For the primary  endpoint (incidence of all SAEs , expectant mother and infant )a point 
estimate and 95% confidence interval (by the Wilson score method) for the proportion of 
subjects with one or more SAE will be provided .In addition, the SAEs will be listed.
No statistical hy potheses will be tested.
9.7.3.2
Secondary Endpoint s
Descriptive methods, mainly  frequency  tables, w ill be used for the secondary  safet y 
endpoints (see Section 9.1.2 ).
9.7.4
Planned Interim Analysis of the Study
Regular study  progress information will be provided in Europe with each Periodic Safet y 
Update Report ( PSUR ), but at least annual ly. In the USA ,this information will be made 
available with the annual status report.
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 49of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL9.8Quality C ontrol
9.8.1 Investigator’s Responsib ility
The investigator will comply  with the protocol (which has been approved/given favorable 
opinion by  the competent/health authority  and/or EC, as applicable ), and applicable 
regulatory  requirements as described in the Registry /Non- interventional Trial Agreement . 
The investigator is ultimately  responsible for the conduct of all aspects of the study  at the 
study  site and verifies b y signature the integrit y of all data transmitted to the 
MAH /MAH’s representative(s) . The term “investigator” as used in this protocol ,as well 
as in other study  documents, refers to the investigator or authorized study  personnel that 
the investigator has designated to perform certain duties. Sub -investigators ,or other 
authorized study  personnel, are eligible to sign for the in vestigator, except where the 
investigator’s signature is specificall y required.
The investigator will retain study  documentation and data (paper and electronic forms) in 
accordance with applicable regulatory  requirements and the document and data retention
policy , as described in the Registry /Non- interventional Trial Agreement.
9.8.2 Direct Access to Source Data/Documents
The investigator/study  site will cooperate and provide direct access to study documents 
and data, including source documentation for monitoring by the study  monitor, audits by  
the MAH and/or itsrepresentatives, review by  the EC, and inspections by  applicable 
regulatory  authorities, as described in the Registry/Non -interventional Trial Agreement . 
If contacted b y an applicable regulatory  authorit y, the investigator will notify  the 
MAH /MAH’s representative(s) of contact, cooperate with the authorit y, provide the 
MAH /MAH’s representative(s) with copies of all documents received from the authority , 
and allow the MAH /MAH’s representative(s) to comment on any  responses, as described 
in the Registry /Non -interventional Trial Agreement .
9.8.3 Training
The study  monitor will ensure that the investigator and study  site personnel understand 
all requirements of the protocol and his/her regulatory  responsibilities as an investigator. 
Training may  be provided at an investigator’s meeting, at the study  site, and/or by  
instruction manuals. I n addition, the study  monitor will be available for consultation with 
the investigator and will serve as the liaison between the stu dy site and the MAH /MAH’s 
representative(s) .
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 50of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL9.8.4 Monitoring
The study  monitor is responsible for ensuring and verify ing that each study  site conducts 
the study  according to the protocol, standard operating procedures, other written 
instructions/agreements, and applicable regulatory guidelines/requirements. The 
investigator will permit the study  monitor to visit the study  site at appropriate intervals, 
as described in the Registry /Non- interventional Trial Agreement . Monitoring processes 
specific to the stud y wil l be described in the clinical monitoring plan (see Section 14.1). 
9.8.5 Auditing
The MAH and/or 
MAH ’srepresentatives may conduct audits to evaluate study  conduct 
and compliance with the protocol, standard operating procedures, other written 
instructions/agree ments,  and applicable regulatory  guidelines/requirements. The 
investigator will permit auditors to visit the study  site, as described in the Registry /Non-
interventional Trial Agreement . Auditing processes specific to the stud y will be described 
in the cli nical quality  management plan (see Section 14.1) .
9.8.6 Non-Compliance with the Protocol
If monitoring and/or auditing identify  serious and/or persistent non
-compliance with the 
protocol, the MAH may terminate the investigator’s participation . 
9.9 Limitations of the R esearch M ethods
In the EU, Hy Qvia should only be given with caution to pregnant women. In the USA, 
HyQvia should be given to a pregnant woman only  if clearl y indicated. The number of 
pregnancies occurring is expected to be low. The refore the registry  could b e terminated 
with asmall sample size and limited data . Also, as an observati onal study , there is no 
means to control the amount of data that are entered by  thelead phy sician or other 
physicians.
9.10 Other 
Aspects
This paragraph is not applicable, as all as pects of the research method are covered by  the 
previous sections. 
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 51of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL10.PROTECTION OF HUMAN SUBJECTS
10.1 Compliance Statement
This study  will be conducted in accordance with this protocol and applicable national 
andlocal requirements for good pharmacovigilance practices .27
10.2 Subject Privacy
The investigator will comply  with applicable subject privacy  regulations/guidance as 
described in the Registry/Non -interventional Trial Agreement .
10.3 Institutional Review Board/ Ethics Committee (s)and Regulatory Authorities
Before enrollment of patients into this study , the protocol , informed consent form, any
promotional material/advertisements, and an y other written information to be provided 
will be reviewed and approved/given favorable opinion by  the Institutional Review Board 
(IRB)/ EC and applicable regulatory  authorities. The IRB/EC’s composition, or a 
statement that the IRB/ EC’s composition meets applicable regulatory  criteria , will be 
documented. The stud y will commence onl y upon the MAH ’s/MAH’s representative(s) ’s
receipt of approval/favorable opinion from the IRB/EC and, if required, upon the 
MAH ’s/MAH ’s representative(s) ’snotification of applicable regulatory  authority (ies) 
approval, as described in the Registry /Non- interventional Trial Agreement . 
If the protocol or an y other information given to the subject is amended, the revised 
documents will be reviewed and approved/given favorable opinion by  the IRB/EC 
andrelevant regulatory  authorities, where applicable. The protocol amendment will 
only be implemented upon the MAH ’s/MAH’s representative(s) ’sreceipt of approval 
and, if required, upon the MAH ’s/MAH’s representative(s) ’s notification of applicable 
regulatory  authority (ies) approval.
10.4 Informed Consent
Investigators will choose patients for enrollment considering the stud y eligibility  
criteria. The investigator will exercise no selectivity  so that no bias is introduced 
from this source. 
All patients and/or their legally  authorized representative must signan informed 
consent form before entering into the study according to applicable regulatory  
requirements. An assent form may  be provided and shoul d be signed b y patients 
lessthan 18 years of age. Before use, the informed consent form will be reviewed 
bytheMAH /MAH’s representative(s) and approved by  the IRB/ EC and 
regulatory authority (ies), where applicable, (see Section 10.3). 
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 52of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALTheinformed consent form will include a comprehensive explanation of the study
without any  exculpatory  statements, in accordance with the elements required b y 
applicable regulatory  requirements. Patients or their legally  authorized representative(s) 
will be allowed sufficient time to consider participation in the study . By signing the 
informed consent form, patients or their legall y authorized representative(s) agree to the 
use of their data for the study , unless they  withdraw voluntarily  or are terminated from 
the study  for any  reason.
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 53of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL11.MANAGEMENT AND REPOR TING OF ADVERSE EVEN TS/ADVERSE 
REACTIONS
11.1 Assessment of Adverse Even ts
Each AE from enrollment until study  completion/ discontinuation will be described on the 
AE CRF using the medical diagnosis (preferred), or, if no diagnosis could be established 
at the time of reporting the AE, a s ymptom or sign, in standard medical terminology  in 
order to avoid the use of vague, ambiguous, or colloquial expressions (see definitions in 
Section 11.2). 
If a pregnant woman experience s an AE between confirmation of pregnancy and 
enrollment, or an infant experiences an AE between birth and enrollment, 
the investigator 
willenter the data on the AE/SAE form in the eCRF. These AEs willbe treated as study-
solicited events.
Each AE will be evaluated by  the investigator for:
Seriousness as defin ed in Section 11.2.2, 
Severity  as defined in Section 11.2.4
Causal relationship to medicinal product exposure as defined in Section 11.2.5
Foreach AE, the outcome (ie, recovering/resolving, recovered/resolved, 
recovered/resolved with sequelae, not recovered/not resolved, fatal, unknown) and if 
applicable action taken (ie, dose increased, dose not changed, dose reduced, drug 
interrupted, drug wi thdrawn, not applicable, or unknown) will also be recorded on the AE 
CRF. Recovering/resolving AEs will be followed until resolution, medically  stabilized, or 
30 day s after the study  completion/termination visit, whichever comes first
. If the 
severit y rati ng for an ongoing AE changes before the event resolves, the original AE 
report will be revised (ie, the event will not be reported as separate AE). During the 
course of an y AE , the highest severit y rating will be reported.
Deviations from the dosage specif ied in the package insert /SPC (including overdosing
(by >20%) ,underdosing ,
abuse, and withdrawal treatment errors (including incorrect 
route of administration, use of an incorrect product, and deviations from the dosing 
schedule defined in the package insert /SPC), failures of expected pharmacological 
actions, and unexpected therapeutic or clinical benefits will be followed with regard to 
occurrence of AEs, lack of efficacy, and/or other observations because these events may  
be reportable to regulatory  authorities.
If an informed consent has also been signed for the child, then AEs for the child will also 
be assessed and captured as described in Section 11, from birth until study  
completion /discontinuation for the child.
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 54of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL11.2 Definitions
11.2.1 Adverse Events
An AE is defined as an y untoward medical occurrence in a subject administered a 
medicinal product that does not necessarily  have a causal relationship with the treatment.  
An AE can therefore be any  unfavorable and unintended sign (eg, an abnormal laboratory  
finding), s ymptom (eg, rash, pain, discomfort, fever, dizziness, etc.), disease (eg, 
peritonitis, bacteremia, etc.), or outcome of death temporall y associated with the use of a 
medicinal product , whether or not considered causally  related to the medicinal product.
11.2.2 Serious Adverse Event
A serious adverse event (SAE) is defined as an untoward medical occurrence that at an y 
dose meets one or more of the following criteria:
Outcome is fatal/results in death (including fetal death)
Is life -threatening –
defined as an event in which the subject was, in the judgment 
of the investigator, at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death had it been more severe
Requires inpatient hospitalization or results in prolongation of an existing 
hospitalization –inpatient hospitalization refers to any inpatient admission, 
regardless of length of stay
Results in persistent or significant disability /incapacity  (ie, a substantial disruption 
of a person’s ability  to conduct normal life functions)
Is a congenital anomal y/birth defect
Is a medicall y importan t event –a medical event that may  not be immediately  life-
threatening or result in death or require hospitalization but may  jeopardize the 
subject or may  require medical or surgical intervention to prevent one of the other 
outcomes listed in the definitio ns above. Examples of such events are: 
Intensive treatment in an emergency  room or at home for allergic 
bronchospasm, blood d yscrasias, or convulsions that do not result in 
hospitalization, or development of drug dependence or drug abuse
Reviewed and conf irmed seroconversi on for human immunodeficiency  virus 
(HIV), hepatitis A virus (HAV) ,hepatitis B virus (HBV), hepatitis C virus 
(HCV), hepatitis E virus (HEV), or parvovirus B19 (B19V).
Thro mboembolic events (eg, deep vein thrombosis, pulmonary  embolism, 
myocardial infarction, transient ischaemic attack, stroke, etc.)
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 55of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALDiagnosis of hemoly tic anemia, reviewed and confirmed by  the study  site 
using standard laboratory assessments
Any pregnancy  complication or pregnancy  termination by  therapeutic, elective or 
spontaneous abortion shall be considered an SAE.
11.2.3 Non-Serious Adverse Event
A non-serious AE is an AE that does not meet the criteria of an SAE.
11.2.4 Severity
The investigator will assess the severit y of each AE using his/her clinical expertise and 
judgment based on the most appropriate description below:
Mild
The AE is a transient discomfort and does not interfere in a significant 
manner with the subject’s normal functioning level.
The AE resolves spontaneously  or may  require minimal therapeutic 
intervention.
Moderate
The AE produces limited impairment of function and may  require therapeutic 
intervention.
The AE produces no sequel a/sequelae.
Severe
The AE results in a marked impairment of function and may  lead to 
temporary  inability  to resume usua l life pattern.
The AE produces sequel a/sequelae , which require (prolonged) therapeutic 
intervention.
These severity  definitions will also be used to assess the severity of an AE with a study-
related procedure(s), if necessary .
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 56of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL11.2.5 Causality
Causality  is a det ermination of whether there is a reasonable possibility  that the medicinal
product (H yQvia or Human normal immunoglobulin or alternative treatment ) is 
etiologicall y related to/associated with the AE. Causality  assessment includes, eg,
assessment of tempora l relationships, dechallenge/rechallenge information, association 
(or lack of association) with underly ing disease, presence (or absence) of amore likely  
cause, and ph ysiological plausibility . For each AE, the investigator will assess the causal 
relationship between the medicinal product and the AE using his/her clinical expertise 
and judgment according to the following most appropriate algorithm for the 
circumstances of the AE:
Not related (both circumstances must be met)
Is due to underl ying or concurren
t illness, complications, concurrent 
treatments, or effects of concurrent drugs
Is not associated with the medicinal product (ie, does not follow a reasonable 
temporal relationship to the administration of medicinal product or has a 
much more likel y alternative etiology ). 
Unlikely  related (either 1 or both circumstances are met)
Has little or no temporal relationship to the medicinal product
A more likel y alternative etiology  exists
Possibly  related (both circumstances must be met)
Follows a reasonable temporal relationship to the administration of medicinal 
product
An alternative etiology  is equally  or less likel y compared to the potential 
relationship to the medicinal product
Probably  related (both circumstances must b e met)
Follows a strong temporal relationship to the administration of medicinal 
product , which may  include but is not limited to the following: 
oReappearance of a similar reaction upon re -administration (positive 
rechallenge)
oPositive results in a drug se nsitivity  test (skin test, etc.)
oToxic level of the medicinal product as evidenced by  measurement of the 
medicinal product concentrations in the blood or other bodily  fluid
Another etiology  is unlikely  or significantl y less likely
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 57of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALFor events assessed as n ot related or unlikel y related, the investigator shall provide the 
alternative etiology .
11.2.6 Safety Reporting
Adverse Events/ SAEs will be assessed at all stud y visits as outlined in the Schedule of 
Study  Assessments (see Table 2) and Section 11.1 above.
Adverse Events/ SAEs are to be recorded on the AE page of the eCRF. Each event should 
be recorded separatel y.
Any SAE, including death due to any  cause, which occurs during this study , whether or 
not related to the stud y product, must be reported immediately  (within 24 hours of the 
study  center’s first knowledge of the event). Any Adverse Event which occurs during this 
study , whether or not related to the study  product, is to be entered in the eCRF, within 5 
business day s
. 
If the site is coordinated by the MAH’s representative, SAEs must be reported o n the 
paper SAE report form and transmitted to the MAH/MAH’s representative immediately
(see SAE report form for contact information) . Any AE will be report ed on the Non-
Serious AE r eport f ormand transmitted to the MAH’s representative for entry  in the EDC 
system within 5 business day s (see Non- Serious Adverse Event Report Form for contact 
information) .
All Adverse Events/SAEs must be reported via the EDC sy stem by  completing the 
relevant eCRF page(s) in English. Once the Adverse Event/SAE has been recorded in the 
EDC sy stem, the Sponsor and other designated recipients will be informed of the event 
automatically . 
For instances in which the EDC may  become unavailable, SAEs must be reported using 
the back -up paper SAE Report Form to meet the 24 hour timeline requirement .If the 
eCRF is not available for more than 14 business day s, then  AEs should be reported using 
the back -up paper Non- serious Adverse Event Report Form (contacts and instructions to 
be provided in separate documentation). Once the EDC becomes available, the 
site/MAH’s representative must enter all Adverse Event/SAE data as reported on the 
back -up paper Adverse Event /SAE report form on the applicable eCRF pages.
The initial Adverse Event/ SAE information reported on the applicable eCRF pages (or 
back -up Adverse Event/ SAE Report Form if applicable) must at least include the 
following:
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 58of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALProtocol Number
Subje ct identification number and demographics (gender, age at onset of event 
and/or date of birth)
Study  drug exposure
Medical Term for Event (Diagnosis preferabl y) 
Description of the (S)AE, including:
Date of onset
(S)AE Treatment (drug, dose, route of admin istration)
Causal relationship by the Investigator
Measures taken (i.e., action taken regarding investigational product in direct 
relationship to the AE)
Seriousness criteria (i.e, death, life- threatening, or other criterion), if applicable
Cause of death 
Autopsy  findings (if available)
Name, address, fax number, email, and telephone number of the reporting 
Investigator (for paper SAE Report Forms)
11.2.7 Preexisting Diseases
Preexisting diseases that are present before entry  into the study  are described in the 
medical history (except study -solicited events, which should be recorded as AEs/SA Es, 
see Section 11.1) .Those t hat manifest with the same severit y, frequency , or duration 
during the stud y, will not be recorded as AEs/SAEs. However,w hen there is an increase 
in the severit y
,duration, or frequency of a preexisting disease, the event must be 
described on the AE CRF.
11.2.8 Unexpected Adverse Events
An unexpected adverse event is an AE whose nature, severity, specificit y, or outcome is 
not consistent with the term, representation, or description used in the Reference Safet y 
Information ( eg, package insert /SPC). “Unexpected” als o refers to the AEs that are 
mentioned in the package insert /SPC asoccurring with a class of drug or as anticipated 
from the pharmacological properties of the drug, but are not specificall y mentioned as 
occurring with the particular medicinal product under investigation.
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 59of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL11.3 Non-Medical C omplaints
A non-medical complaint ( NMC )is an y alleged product deficiency  that relates to 
identity , quality , durability , reliability , safet
y, effectiveness, or performance of the 
product but doesnot result in an AE. NMCs include but are not limited to the following:
Afailure of a product to exhibit its expected pharmacological activity  and/or design 
function 
Missing components
Damage to the product or unit carton
A mislabeled product ( potential counterfeiting/ tampering)
A bacteriological, chemical, or ph ysical change or deterioration of the product that 
causesit to malfunction or to present a hazard or fail to meet label claims
Any NMCs of the 
product will be documented on a nNMC form and reported to the 
MAH /MAH’s repre sentative(s) within 1 busines s day . If requested, defective product(s) 
will be returned to the MAH /MAH’s representative(s) for inspection and analy sis 
according to procedures.
12.PLANS FOR DISSEMINAT ING AND COMMUNICATING STUDY RESULTS
The CHMP requested a pre liminary  study  report to be performed with each PSUR. The 
FDA requires an annual status report. The final report 
is estimated for 2021.
The final data will be in the publicly  available database of the European Network of 
Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) , details see 
page 1. The final data will also be communicated directl y to the subjects b y mail where 
required as per local regulations.
The investigator will comply  with the publication policy  as described in the 
Registry /Non-interventional Trial Agreement.
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 60of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL13.REFERENCES
1. Al-Herz W, Bousfiha A, Casanova J L et al. Primary  immunodeficiency  diseases: an 
update on the classification from the International Union of I mmunological 
Societies Expert Committee fo r Primary  Immunodeficiency . Front. Immunol. 
2011;2:54.
Link to Publisher´s Site: 
http://www.frontiersin.org/primary _immunodeficiencies/10.3389/fimmu.2011.0005
4/full
2. Rozman C, Montserrat E. Chronic ly mphocy tic leukemia. N.Engl.J.Med. 
1995;333:1052-1057.
3. Kyle RA, Rajkumar SV. Multiple my eloma. N.Engl.J.Med. 2004;351:1860 -1873.
4. Gardulf A, Nicolay  U, Asensio O et al. Rapid subcutaneous IgG replacement 
therap y is effective and safe in children and adults with primary 
immunodeficiencies -A prospect ive multi -national study . J.Clin.I mmunol. 
2006;26:177 -185.
5. Ochs HD, Gupta S, Kiessling P et al. Safet y and efficacy  of self -administered 
subcutaneous immunoglobulin in patients with primary  immunodeficiency diseases. 
J.Clin.I mmunol. 2006;26:265 -273.
6. Berger M, Cupps TR, Fauci AS. I mmunoglobulin replacement therapy  by slow 
subcutaneous infusion. Ann.I ntern.Med. 1980;93:55-56.
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 61of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL7. Welch MJ, Stiehm ER. Slow subcutaneous immunoglobulin therap y in a patient 
with reactions to intramuscular immunglobulin . J.Clin.I mmunol. 1983;3:285 -286.
8. Roord JJ, van der Meer JW, Kuis W et al. Home treatment in patients with antibody  
deficiency  by slow subcutaneous infusion of gammaglobulin. Lancet 1982;1:689 -
690.
9. Gardulf A, Björvell H, Gustafson R, Hammarström L, Smith CI . Safety  of rapid 
subcutaneous gammaglobulin infusions in patients with primary  antibody  
deficiency . Immunodeficiency . 1993;4:81 -84.
10. Gustafson R, Gardulf A, Hansen S et al. Rapid subcutaneous immunoglobulin 
administration every  second week results in high and stable serum immunoglobulin 
G levels in patients with primary  antibody  deficiencies. Clin.Exp.I mmunol. 
2008;152:274-279.
11. Gardulf A, Andersen V, Björkander J et al. Subcutaneous immunoglobulin 
replacement in patients with primary  antibody  deficiencies: safet y and costs. L ancet 
1995;345:365-369.
12. Gardulf A, Hammarström L , Smith CI . Home treatment of 
hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. 
Lancet 1991;338:162 -166.
13. Gardulf A, Hammarström L .Subcutaneous administration of immunoglobulins.  
What are the advantages? Clin.I mmunother. 1996;6:108 -116.
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 62of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL14. Schiff RI , Rudd C. Alterations in the half -life and clearance of IgG during therap y 
with intravenous gamma -globulin in 16 patients with severe primary  humoral 
immunodeficiency . J.Clin.I mmunol. 1986;6:256 -264.
15. Smith GN, Griffiths B, Mollison D, Mollison PL. Uptake of IgG after intramuscular 
and subcutaneous injection. Lancet 1972;1:1208 -1212.
16. ZLB Behring. Immune Globulin Subcutaneous (Human), Vivaglobin®. US Label.  
8. 2006. 
Link to Publisher´s Site: 
http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/Appr
ovedProducts/L icensedProductsBLAs/FractionatedPlasmaProducts/ucm070360.pdf
17. Wasserman RL , Melamed I , Nelson RP, Jr. et al. Pharmacokinetics of subcutaneous 
IgPro20 in patients with primary  immunodeficiency . Clin.Pharmacokinet. 
2011;50:405 -414.
18. Supersaxo A, Hein WR, Steffen H. Effect of molecular weight on the l ymphatic 
absorption of water -soluble compounds following subcutaneous administration. 
Pharm.Res. 1990;7:167 -169.
19. Olsson O, L öjgren O. Hyaluronidase as a factor hastening the spread and absorption 
of water -soluble radiopaque substances deposited intracutaneousl y, subcutaneousl y, 
or intramuscular ly. Acta Radiol. 1949;31:250 -256.
20. Thomas JR, Yocum RC, Haller MF, von Gunten CF. Assessing the role of human 
recombinant h yaluronidase in gravity- driven subcutaneous hy dration: The INFUSE -
LR Study . J.Palliat.Med. 2007;10:1312 -1320.
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 63of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL21. Shpilberg O, Jackisch C. Subcutaneous administration of rituximab (MabThera) and 
trastuzumab (Herceptin) using h yaluronidase. Br.J.Cancer 2013;109:1556 -1561.
22. Yocum RC, Kennard D, Heiner LS. Assessment and implication of the allergic 
sensitivity  to a single dose of recombinant human hy aluronidase injection: a double -
blind, placebo -controlled clinical trial. J.I nfus.Nurs. 2007;30:293 -299.
23. Rosengren S, Souratha J, Conway  D, Sugarman BJ, Muchmore DB. Prevalence of 
pre-existing antibodies reactive to rHuPh20 in the normal adult population: An 
interim anal ysis of an ongoing survey  study  [abstract]. J.Clin.I mmunol. 
2014;34:379.
24. Wasserman RL , Melamed I , Stein MR et al. Recombinant human hy aluronidase -
facilitated subcutaneous infusion of human immunoglobulins f or primary  
immunodeficiency . J.Allergy  Clin.I mmunol. 2012;30:951 -957.
25. Committee for Medical Products for Human Use. Guideline on the Exposure to 
Medicinal Products during Pregnancy : Need for Post -Authorisation Data. 
EMA/CHMP/313666/2005. 11-14-2005. London, England, European Medicines 
Agency  (EMEA). 
Link to Publisher´s Site: 
http://www.ema.europa.eu/docs/en_GB/document_library /Regulatory _and_procedu
ral_guideline/2009/11/WC500011303.pdf
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 64of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL26. U.S.Department of Health and Human Services, Food and Drug Administration, 
and Center for Biologics Evaluation and Research. Guidance for industry : 
Establishing pregnancy  exposure registeries.  27. 2002. Rockville, MD, U.S. 
Department of Health and Human Services, Food and Drug Administration (FDA). 
27. Europea n Medicines Agency  and Heads of Medicines Agencies. Guideline on good 
pharmacovigilance practices (GPV): Module VIII post- authorisation safet y studies. 
EMA/813938/2011. 4-19- 2013.  European Medicines Agency  (EMEA). 
Link to Publisher´s Site: 
http://www.ema .europa.eu/docs/en_GB/document_library /Scientific_guideline/201
2/06/WC500129137.pdf
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 65of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL14.ANNEXE S
14.1 List of Stand -Alone Documents
No. Document Reference No. Date Title
1 Version 1 27 JAN 2015 Data Management Plan
2 Version 1 29 JAN 2015 Recruitment Strategy Plan
3 Version 1 04 MAR 2015 Clinical Monitoring Plan
4 Version 1 22 MAR 2015 Communication Plan
5 Version 1 23 MAR 2015 Clinical Quality Management Plan
6 Version 1 12 AUG 2015 Safety Management Plan
7 Version 2 24 SEP 2015 Laboratory Specifications Docum ent
8 NA 28 SEP 2015 Study Organization
9 NA Not yet finalized Statistical Analysis Plan 
14.2 ENCePP Checklist for Study P rotocols
Refer to the completed ENCePP Checklist .
14.3 Additional Information
Not applicable.
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 66of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVAL14.4 Summary of Changes
PROTOCOL 161301
AMENDMENT 3 - 22 OCT 2015
Replaces : Amendment 2version 09 APR 2015
In this section, changes from the previous version of the Protocol, dated 09 APR 2015 ,
are described and their rationale is given.
1.Throughout the document
Descripti on of Change : Minor grammatical and/or administrative changes have 
been made. 
Purpose for Change : To improve the readability  and/or clarit y of the protocol.
2.Title Page, SAE and AE reporting, Section 11.2.6 Safety Reporting
Description of Change :The description of the SAE reporting process was 
changed. AE reporting in case eCRF is not available is described.
Purpose for Change : To accommodate SAE/AE reporting procedures both for 
electronic SAE /AE reporting as well as SAE/AE reporting in case eCRF is not 
available.
3.Section 4Abstract , Sec tion 7.1 Medicinal Product Safety Profile, 
Section 9.1Study Design, 9.2 Setting, 9.9 Limitations of the Research Metho d
Description of Change :Text adapted according the revised EU SPC
Purpose for Change :Additional data have become available and are reflected in 
the updated version of the SPC/EU package insert information. L anguage 
regarding pregnancy , breast- feeding and fertility  was changed.
4.Section 4, Section 9.1 Study Design, 
Section 9.3.4 Clinical Laboratory Parameters
Description of Change :The language was modified regarding measurement of 
binding and neutralizing rHuPH20 antibodies :For subjects with an anti -rHuPH20 
antibody  titer ≥ 160, also neutralizing antibodies will be measured. In addition, 
antibody  characteri zation will be performed in subjects who test positive 
≥ 10,000.
Purpose for Change :To specify  the t ype of assessment for anti- rHuPH20 
antibodies to be performed.
For non-commercial use only
Human normal immunoglobulin/Alternative Treatment Page 67of 67
Non-Interventional Study Pr otocol Identifier: 161301 22 OCT 2015
BAXALTA CONFIDENTIAL –RESTRICTED: DO NOT D ISTRIBUTE WITHOUT PR IOR APPROVALINVESTIGATOR ACKNOWL EDGEMENT
Human Normal Immunoglobulin
Pregnancy Registry to collect Long- Term Safety Data from Women  treated with 
HyQvia 
PROTOCOL IDENTIFIER: 161301
AMENDMENT 3: 22 OCT 2015
Replaces
AMENDMENT 2: 0 9 APR 2015
AMENDMENT 1: 03 FEB 2015
Original : 2013 JUN 27
OTHER PROTOCOL ID(s)
Study ID: [REMOVED]
EU PAS: ENCePP/SDPP/5798
IND/IDE NUMBER : 013840
By signing below, the investigator acknowledges that he/she has read and understands 
this protocol, and will comply  with the requirements for obtaining  informed consent 
from all study
 subjects pr ior to initiating an y protocol -specific procedures, obtaining 
written initial and ongoing ethics committee (s) protocol review and approval, 
understands and abides by  the requirements for maintenance of source documentation, 
and provides assurance that this study  will be conducted according to all requirements as 
defined in this protocol, Registry /Non- interventional Trial Agreement , good 
pharmacovigilance practices, and all applicable regulatory  requirements.
Signature of Principal Investigator Date
Print Name of Principal Investigator
Signature of MAH Representative Date
Barbara Valenta- Singer, MD
Vice President, Clinical Development
For non-commercial use only